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PURPOSE OF WORK AND PLAN OF WORK 
 
PURPOSE OF WORK 
 
¾ Etodolac, is a nonsteroidal anti-inflammatory drug (NSAIDs), used 
in the treatment of arthritis and the alleviation of pain1. 
¾ Etodolac is rapidly absorbed after oral administration. 
¾ The onset of action is 30 minutes and Cmax achieved within 1-2 
hours of administration of tablets or capsules. 
¾ The bioavailability of Etodolac from tablets and capsules is 100% 
relative to oral solution. 
¾ Pharmacokinetics of Etodolac exhibit dose proportionality over the 
100-300 mg dose range for immediate release formulation2. 
¾ Fast track cardiac anesthesia requires lower dose of opioids in the 
peri and postoperative period. 
¾ The oral use of Etodolac with rectal buprenorphine reduces 
postoperative pain scores immediately after fast track cardiac 
surgery. 
¾ The faster the release of Etodolac from the dosage form is better for 
the management of pain in postoperative cardiac surgery cases3. 
¾ Etodolac is safe over other NSAIDs and it has less ulcerogenic 
activity4. 
¾ As Etodolac immediate release 300 mg tablets formulation is not 
available globally, the present study is attempted to prepare 
immediate release tablets of Etodolac.  
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¾ By using superdisintegrants such as polyplasdone XL-10 
(crospovidone) and sodium starch glycolate were added in three 
different methods: 
 • Intragranular (before granulation) 
 • Extra granular (after granulation) and  
 • Partly Intra and Extragranular method of addition 
¾ And these superdisintegrants were added in three different ratios’ 
(2%, 4%, and 6%) to develop a stable immediate release 
formulation by wet granulation method. So as to increase the rate of 
drug release from the dosage form to increase the dissolution rate. 
 
PLAN OF WORK 
9 Literature survey on Etodolac drug and immediate release 
dosage forms. 
9 Preformulation studies. 
9 Formulation of Etodolac immediate release tablets by 
intragranular, extragranular, and partly intra and extragranular 
method of addition, by using superdisintegrants such as 
(polyplasdone XL-10) crospovidone and sodium starch glycolate 
at three different ratios (2%, 4%, and 6%). 
9 Evaluation tests. 
9 Stability studies. 
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INTRODUCTION 
 
THE HISTORICAL BACKGROUND OF IMMEDIATE 
RELEASE TABLETS 
 Since man first began to treat illness using oral administration of 
herbs and other available materials, there have been a problem of how to 
take the medicines because many drugs, whether natural or synthetic, are 
bitter. Many of early developments in formulations were designed with 
taste masking and convenience in mind. We formulate to convert bulk 
drugs into medicines that the patient can use. In case of oral 
administration, both tablets and capsules are convenient for patients as 
they allow self-medication and can be easily designed to mask any 
unpleasant taste. Besides tablets and capsules, there are powders, 
usually taken dispersed in water. But tablets and capsules are 
comparatively recent developments. In the past drugs were formulated as 
powders, cachets (made of rice starch), and pillules (pills). Tablets and 
capsules are used because, in many respects, they are easier and can be 
manufactured at high speed on today’s modern equipment. 
 Tablets can be designed for use as immediate release products or 
by suitable modification of the composition and manufacturing process, 
can also be designed as modified release products, with many different 
potential release patterns. 
 However, for immediate release tablets, tablet disintegrants play an 
important role in ensuring that the tablet matrix break up on contact with 
the fluid in the stomach to allow the release of the active drug which then 
become available, in whole or in part, for absorption from the 
gastrointestinal tract (GIT). Although most drugs are absorbed from the 
GIT after passing through the stomach, it is nevertheless important with 
immediate release products that the tablet disintegrates properly in the 
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stomach to release the drug and allow it to be absorbed quickly after 
passing through the pyloric sphincter and on into duodenum and beyond5. 
 
IMMEDIATE RELEASE TABLETS 
Definition 
 Tablet may be defined as the solid unit dosage form of medicament 
with or without suitable diluents and prepared either by molding or by 
compression. In "pharmaceutical chemist" terminology 
 A tablet is a combination of ingredients that is compressed into a 
solid mass. The basic components of an immediate release 
pharmaceutical tablet are active drug substances and other excipients. 
 
ADVANTAGES OF TABLETS 
 Tablets are unit dosage forms that provide an accurate, stable dose 
with greatest precision and least content variability. 
 Tablets are easy to use, handle and carry by the patient. 
 Tablets are attractive and elegant in appearance. 
 Tablets are the most stable dosage form with respect to their 
physical, chemical and microbiological attributes. 
 The manufacturing cost of tablets is low as compared to other 
dosage form and their manufacturing speed is also quite high. 
 The packaging and shipping of tablets is comparatively easy and 
cheap. 
 The unpleasant taste and odor of medicament(s) can be easily 
masked by sugar-coating. 
 The incompatibilities of medicament(s) and their deterioration due 
to environmental factors are less in case of tablet. 
 Whenever a fractional dose is required, tablets are divided into 
halves and quarters by drawing lines during manufacturing to 
facilitate breakage. 
Chapter 2  Introduction 
 5
 They are more suitable for large scale production than other oral 
dosage forms. 
 Tablets provide administration of even minute dose of drug in an 
accurate amount. 
 Their identification is probably the easiest because of variety of 
shapes and colors. 
 Tablets are formulated with certain special release profile products 
such as enteric or delayed release products. 
 They are economical as their cost is lowest as compared to other 
oral dosage forms. 
 
DISADVANTAGES OF TABLETS 
 Drugs that are amorphous in nature or have low density character 
are difficult to compress into tablet. 
 Hygroscopic drugs are not suitable candidate for compressed 
tablets. 
 Drugs having poor wetting properties, slow dissolution profile and 
high optimal gastro intestinal absorption are difficult or impossible to 
formulate as a tablet. 
 Drugs having bitter taste and objectionable odor requires special 
treatment like coating or encapsulation which may increase their 
production cost. 
 Some drugs which preferably get absorbed from the upper part of 
GIT may cause bioavailability problem in tablet dosage form. 
 Swallowing of tablets especially by children and critically ill patients 
is very difficult. 
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TYPES AND CLASSES OF TABLETS6 
 
TABLE NO. 1: TYPES AND CLASSES OF TABLETS 
Oral Tablets for ingestion 
9 Compressed Tablets or Standard Compressed Tablets. 
9 Multiple Compressed Tablets (MCT). 
9 Layered Tablets. 
9 Compression – Coated Tablets. 
9 Repeated – Action Tablets. 
9 Delayed – Action and Enteric Coated Tablets. 
9 Sugar- and Chocolate- Coated Tablets. 
9 Film- Coated Tablets. 
9 Chewable Tablets 
Tablets Used in the Oral Cavity 
9 Sublingual Tablets. 
9 Buccal Tablets. 
9 Troches and Lozenges. 
9 Dental cones. 
Tablets Administered by Other Routes 
9 Implantation Tablets. 
9 Vaginal Tablets. 
Tablets Used to Prepare Solutions 
9 Effervescent Tablets. 
9 Dispensing Tablets (DT). 
9 Hypodermic Tablets (HT). 
9 Tablet Triturates (TT). 
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VARIOUS EXCIPIENTS USED IN TABLET FORMULATION AND THEIR 
FUNCTIONALITIES 
 Excipient means any component other than the active 
pharmaceutical ingredient(s) intentionally added to the formulation of a 
dosage form. Excipients play a crucial role in design of the delivery 
system, determining its quality and performance. 
 
TABLE NO. 2: EXCIPIENTS AND THEIR FUNCTIONALITIES 
EXCIPIENT FUNCTION 
Diluents or Fillers 
E.g.: Lactose, Mannitol, 
Sorbitol, Dextrose, etc. 
Diluents make the required bulk of the 
tablet when the drug dosage itself is 
inadequate to produce tablets of adequate 
weight and size. 
Binders or Granulating 
agents or Adhesives 
E.g.: Acacia, gelatin, 
Polyvinylpyrrolidone, etc. 
Binders are added to tablet formulations to 
add cohesiveness to powders, thus 
providing the necessary bonding to form 
granules, which under compaction form a 
cohesive mass or a compact which is 
referred to as a tablet. 
Disintegrants 
E.g.: Starch, Clays, 
Cellulose, etc. 
A disintegrant is added to most tablet 
formulations to facilitate a breakup or 
disintegration of the tablet when placed in 
an aqueous environment. 
 
Antifrictional Agents 
Lubricants 
E.g.: Talc, Calcium and 
magnesium stearate, etc. 
Lubricants are intended to reduce the 
friction during tablet formation in a die and 
also during ejection from die cavity. 
Anti-adherents 
E.g.: colloidal silica 
Anti-adherents are added to reduce 
sticking or adhesion of any of the tablet 
granulation or powder to the faces of the 
punches or to the die wall. 
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EXCIPIENT FUNCTION 
Glidants 
E.g.: Silica derivatives - 
colloidal silicon, corn starch, 
etc. 
Glidants are intended to promote the flow 
of tablet granulation or powder mixture 
from hopper to the die cavity by reducing 
friction between the particles. 
MISCELLANEOUS 
Wetting agents / Solubilizers 
E.g.: Polysorbate 80. 
 
Wetting agents are added to tablet 
formulation to aid water uptake during 
disintegration and assist drug dissolution. 
Dissolution retardants 
E.g.: Waxes – bees wax.  
Dissolution retardants as the name 
suggest, retards the dissolution of active 
pharmaceutical ingredient(s) 
Dissolution enhancers 
E.g.: Surfactant and 
solubilizers. 
Dissolution enhancers as the name 
suggest, enhance the dissolution rate of 
active pharmaceutical ingredient(s). 
Adsorbents 
 
Adsorbents are capable of retaining large 
quantities of liquids without becoming wet; 
this property of absorbent allows many oils, 
fluid extracts and eutectic melts to be 
incorporated into tablets. 
Buffers 
E.g.: Sodium hydroxide 
Buffers are added to provide suitable micro 
environmental pH to get improved stability 
and / or bioavailability. 
Antioxidants 
E.g.: Ascorbic acid, sodium 
sulfite, sodium bisulfite, 
butylated hydroxyl toluene, 
etc. 
Antioxidants are added to maintain product 
stability, they act by being preferentially 
oxidized and gradually consumed over 
shelf life of the product. 
Chelating agents 
E.g.: Di sodium edentate, 
Chelating agents are added to protect 
against autoxidation; they act by forming 
complexes with the heavy metal ions which 
are often required to initiate oxidative 
reactions. 
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EXCIPIENT FUNCTION 
Preservatives 
E.g.: Benzyl alcohol, methyl 
paraben, propyl paraben, 
etc. 
Preservatives are added to tablet 
formulation in order to prevent the growth 
of micro-organisms. 
Colours 
E.g.: Food Drug and 
Cosmetic, Drug and 
Cosmetic dyes 
Colours are added to tablet formulation for 
following purposes: to disguise off colour 
drugs, product identification and for 
production of more elegant product. 
Flavours 
E.g.: Peppermint oil 
Flavours are added to tablet formulation in 
order to make them palatable enough in 
case of chewable tablet by improving the 
taste. 
Sweeteners 
E.g.: Saccharin 
Sweeteners are added to tablet formulation 
to improve the taste of chewable tablets. 
 
METHOD OF TABLET PREPARATION 
 There are three general methods of tablet preparation. 
 Direct compression method 
 Dry granulation method 
 Wet granulation method 
 
GRANULATION 
 Granulation may be defined as a size enlargement process which 
converts small particles into physically stronger and larger agglomerates. 
 
IDEAL CHARACTERISTICS OF GRANULES 
 The ideal characteristics of granules include spherical shape, 
smaller particle size distribution with sufficient fines to fill void spaces 
between granules, adequate moisture (between 1-2%), good flow, good 
compressibility and sufficient hardness. The effectiveness of granulation 
depends on the following properties 
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 Particle size of the drug and excipients. 
 Type of binder (strong or weak). 
 Volume of binder (less or more). 
 Wet massing time (less or more). 
 Amount of shear applied. 
 Drying rate (Hydrate formation and polymorphism) 
 
WET GRANULATION 
 The most widely used process of agglomeration in pharmaceutical 
industry is wet granulation. Wet granulation process simply involves wet 
massing of the powder blend with a granulating liquid, wet sizing and 
drying. 
 
IMPORTANT STEPS INVOLVED IN THE WET GRANULATION 
9 Mixing of the drug(s) and excipients. 
9 Preparation of binder solution. 
9 Mixing of binder solution with powder mixture to form wet mass 
screens. 
9 Coarse screening of wet mass using a suitable sieve (6-12). 
9 Drying of moist granules. 
9 Screening of dry granules through a suitable sieve (14-20). 
9 Mixing of screened granules with disintegrant, glidant, and lubricant. 
 
LIMITATION OF WET GRANULATION 
 The greatest disadvantage of wet granulation is its cost. It is an 
expensive process because of labor, time, equipment, energy and 
space requirements. 
 Loss of material during various stages of processing. 
 Stability may be major concern for moisture sensitive or thermo 
labile drugs. 
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 Multiple processing steps add complexity and make validation and 
control difficult. 
 An inherent limitation of wet granulation is that any incompatibility 
between formulation components is aggravated. 
 
SPECIAL WET GRANULATION TECHNIQUES 
¾ High shear mixture granulation. 
¾ Fluid bed granulation. 
¾ Extrusion-spheronization. 
¾ Spray drying. 
 
DISINTEGRATION 
 Bioavailability of a drug depends in absorption of the drug, which is 
affected by solubility of the drug in gastrointestinal fluid and permeability of 
the drug across gastrointestinal membrane. The drugs solubility mainly 
depends on physical – chemical characteristics of the drug. However, the 
rate of drug dissolution is greatly influenced by disintegration of the tablet. 
The drug will dissolve at a slower rate from a non-disintegrating tablet due 
to exposure of limited surface area to the fluid. The disintegration test is an 
official test and hence a batch of tablet must meet the stated requirements 
of disintegration. 
 Disintegrants, are important excipient of the tablet formulation, are 
always added to tablet to induce breakup of tablet when it comes in 
contact with aqueous fluid and this process of desegregation of constituent 
particles before the drug dissolution occurs, is known as disintegration 
process and excipients which induce this process are known as 
disintegrants. The objectives behind addition of disintegrants are to 
increase surface area of the tablet fragments and to overcome cohesive 
forces that keep particles together in a tablet. 
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FIGURE NO. 1: TABLET DISINTEGRATION AND SUBSEQUENT DRUG 
DISSOLUTION 
 
MECHANISM OF TABLET DISINTEGRANTS 
 The tablet breaks to primary particles by one or more of the 
mechanisms listed below: 
 By capillary action. 
 By swelling. 
 Because of heat of wetting. 
 Due to disintegrating particle/particle repulsive forces. 
 Due to deformation. 
 Due to release of gases. 
 By enzymatic action. 
 
BY CAPILLARY ACTION 
 Disintegration by capillary action is always the first step. When we 
put the tablet into suitable aqueous medium, the medium penetrates into 
the tablet and replaces the air adsorbed on the particles, which weakens 
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the intermolecular bond and breaks the tablet into fine particles. Water 
uptake by tablet depends upon hydrophilicity of the drug /excipient and on 
tabletting conditions. For these types of disintegrants maintenance of 
porous structure and low interfacial tension towards aqueous fluid is 
necessary which helps in disintegration by creating a hydrophilic network 
around the drug particles. 
 
BY SWELLING 
 Perhaps the most widely accepted general mechanism of action for 
tablet disintegration is swelling Tablets with high porosity show poor 
disintegration due to lack of adequate swelling force. On the other hand, 
sufficient swelling force is exerted in the tablet with low porosity. It is 
worthwhile to note that if the packing fraction is very high, fluid is unable to 
penetrate in the tablet and disintegration is again slows down. 
 
BECAUSE OF HEAT OF WETTING (AIR EXPANSION) 
 When disintegrants with exothermic properties gets wetted, 
localized stress is generated due to capillary air expansion, which helps in 
disintegration of tablet. This explanation, however, is limited to only a few 
types of disintegrants and can not describe the action of most modern 
disintegrating agents. 
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FIGURE NO. 2: MECHANISM OF WICKING AND SWELLING 
 
DUE TO DISINTEGRATING PARTICLE/PARTICLE REPULSIVE 
FORCES 
 Another mechanism of disintegration attempts to explain the 
swelling of tablet made with ‘non-swellable’ disintegrants. Guyot-Hermann 
has proposed a particle repulsion theory based on the observation that 
non-swelling particle also cause disintegration of tablets. The electric 
repulsive forces between particles are the mechanism of disintegration 
and water is required for it. Researchers found that repulsion is secondary 
to wicking. 
 
DUE TO DEFORMATION 
 Hess had proved that during tablet compression, disintegrated 
particles get deformed and these deformed particles get into their normal 
structure when they come in contact with aqueous media or water. 
Occasionally, the swelling capacity of starch was improved when granules 
were extensively deformed during compression. This increase in size of 
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the deformed particles produces a break up of the tablet. This may be a 
mechanism of starch and has only recently begun to be studied. 
 
 
FIGURE NO. 3: MECHANISM OF DEFORMATION AND REPULSION 
 
DUE TO RELEASE OF GASES 
 Carbon dioxide released within tablets on wetting due to interaction 
between bicarbonate and carbonate with citric acid or tartaric acid. The 
tablet disintegrates due to generation of pressure within the tablet. This 
effervescent mixture is used when pharmacist needs to formulate very 
rapidly dissolving tablets or fast disintegrating tablet. As these 
disintegrants are highly sensitive to small changes in humidity level and 
temperature, strict control of environment is required during manufacturing 
of the tablets. The effervescent blend is either added immediately prior to 
compression or can be added in to two separate fraction of formulation. 
 
BY ENZYMATIC REACTION 
 Here, enzymes presents in the body act as disintegrants. These 
enzymes destroy the binding action of binder and helps in disintegration. 
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DISINTEGRATING ENZYMES 
TABLE NO. 3: DISINTEGRATING ENZYMES 
ENZYMES BINDER 
Amylase Starch 
Protease Gelatin 
Cellulose Cellulose and its derivatives 
Invertase Sucrose 
 
METHODS OF ADDITION OF DISINTEGRANTS 
 The method of addition of disintegrants is also a crucial part. 
Disintegrating agent can be added either prior to granulation 
(intragranular) or prior to compression (after granulation i.e. extragranular) 
or at the both processing steps. Extragranular fraction of disintegrant 
(usually, 50% of total disintegrant requires) facilitates breakup of tablets to 
granules and the intragranular addition of disintegrants produces further 
erosion of the granules to fine particles. 
 
TYPES OF DISINTEGRANTS 
STARCH 
 Starch was the first disintegrating agent widely used in tablet 
manufacturing. Before 1906 potato starch and corn starch were used as 
disintegrants in tablet formulation. The mechanism of action of starch is 
wicking and restoration of deformed starch particles on contact with 
aqueous fluid and in doing so release of certain amount of stress which is 
responsible for disruption of hydrogen bonding formed during compression 
 
PREGELATINIZED STARCH 
 Pregelatinized starch is produced by the hydrolyzing and rupturing 
of the starch grain. It is a directly compressible disintegrants and its 
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optimum concentration is 5-10%. The main mechanism of action of 
Pregelatinized starch is through swelling. 
 
MODIFIED STARCH 
 To have a high swelling properties and faster disintegration, starch 
is modified by carboxy methylation followed by cross linking, which is 
available in market as cross linked starch. One of them is sodium starch 
glycolate. Even low substituted and Primogel, carboxymethyl starches are 
also marketed as Explotab. Mechanism of action of this modified starches 
are rapid and extensive swelling with minimum gelling. And its optimum 
concentration is 4-6 %. If it goes beyond its limit, then it produces viscous 
and gelatinous mass which increases the disintegration time by resisting 
the breakup of tablet. They are highly efficient at low concentration 
because of their greater swelling capacity. 
 
CELLULOSE AND ITS DERIVATIVES 
 Sodium carboxy methylcellulose (NaCMC and Carmelose sodium) 
has highly hydrophilic structure and is soluble in water. But when it is 
modified by internally crosslinking we get modified crosslinked cellulose 
i.e. Croscarmelose sodium which is nearly water insoluble due to cross 
linking. It rapidly swells to 4-8 times its original volume when it comes in 
contact with water. 
 
MICROCRYSTALLINE CELLULOSE (MCC) 
 MCC exhibit very good disintegrating properties because MCC is 
insoluble and act by wicking action. The moisture breaks the hydrogen 
bonding between adjacent bundles of MCC. It also serves as an excellent 
binder and has a tendency to develop static charges in the presence of 
excessive moisture content. Therefore, sometimes it causes separation in 
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granulation. This can be partially overcome by drying the cellulose to 
remove the moisture. 
 
ION-EXCHANGE RESIN 
 Ion exchange resin (Ambrelite IPR-88) has highest water uptake 
capacity than other disintegrating agents like starch and Sodium CMC. It 
has tendency to adsorb certain drugs. 
 
ALGINATES 
 Alginates are hydrophilic colloidal substances which has high 
sorption capacity. Chemically, they are alginic acid and salts of alginic 
acid. Alginic acid is insoluble in water, slightly acidic in reaction. Hence, it 
should be used in only acidic or neutral granulation. Unlike starch and 
MCC, alginates do not retard flow and can be successfully used with 
ascorbic acid, multivitamin formulations and acid salts of organic bases. 
 
MISCELLANEOUS 
 This miscellaneous category includes disintegrants like surfactants, 
gas producing disintegrants and hydrous aluminium silicate. Gas 
producing disintegrating agents is used in soluble tablet, dispersible tablet 
and effervescent tablet. 
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TABLE NO. 4: COMMONLY USED DISINTEGRANTS 
DISINTEGRANTS CONCENTRATION IN GRANULES (%W/W) 
SPECIAL 
COMMENTS 
Starch USP 5-20 Higher amount is 
required, poorly 
compressible 
Starch 1500 5-15 - 
Avicel®(PH 101, PH 
102) 
10-20 Lubricant properties 
and directly 
compressible 
Solka floc® 5-15 Purified wood cellulose
Alginic acid 1-5 Acts by swelling 
Na alginate 2.5-10 Acts by swelling 
Explotab® 2-8 Sodium starch 
glycolate, 
superdisintegrant. 
Polyplasdone®(XL) 0.5-5 Crosslinked PVP 
Amberlite® (IPR 88) 0.5-5 Ion exchange resin 
Methyl cellulose, Na 
CMC, HPMC 
5-10 - 
AC-Di-Sol® 1-3 Direct compression 
2-4 Wet granulation  
Carbon dioxide - Created insitu in 
effervescent tablet 
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SUPERDISINTEGRANTS 
 As days passes, demand for faster disintegrating formulation is 
increased. So, pharmacist needs to formulate disintegrants i.e. 
Superdisintegrants which are effective at low concentration and have 
greater disintegrating efficiency and they are more effective 
intragranularly. But have one drawback that it is hygroscopic therefore not 
used with moisture sensitive drugs. 
 Superdisintegrants break a tablet into smaller fragments increasing 
the surface area of the dosage form and the rate of drug absorption. Ac-
Di-Sol® Croscarmelose sodium was developed to: 
• Enhance drug dissolution by speeding tablet disintegration  
• Provide the highest level of disintegration force at low use levels  
 Utilize dual disintegration mechanisms of wicking and swelling for 
more rapid disintegration. 
 And this superdisintegrants act by swelling and due to swelling 
pressure exerted in the outer direction or radial direction, it causes tablet 
to burst or the accelerated absorption of water leading to an enormous 
increase in the volume of granules to promote disintegration. 
 
FIGURE NO. 4: MECHANISM OF SUPERDISINTEGRANTS BY 
SWELLING 
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TABLE NO. 5: COMMONLY USED SUPERDISINTEGRANTS 
 
SUPERDISINTEGRANTS MECHANISM OF ACTION 
SPECIAL 
COMMENT 
Croscarmelose 
 
Ac-Di-Sol 
Primellose 
Solutab 
Vivasol 
Swells 4-8 folds in < 10 
seconds. 
Swelling and wicking 
both 
Swells in two 
dimensions. 
Direct compression 
or granulation 
 
Starch free 
 
Crospovidone 
Crospovidon M 
Kollidon 
Polyplasdone 
Swells very little and 
returns to original size 
after compression but 
act by capillary action 
Water insoluble and 
spongy in nature so 
get porous tablet 
Sodium starch glycolate 
Explotab 
Primogel 
Swells 7-12 folds in 
<30 seconds 
Swells in three 
dimensions and high 
level serve as 
sustain release 
matrix 
Alginic acid NF 
Satialgine 
Rapid swelling in 
aqueous medium or 
wicking action 
Promote 
disintegration in both 
dry or wet 
granulation 
Soy polysaccharides 
Emcosoy 
 Does not contain 
any starch or sugar. 
Used in nutritional 
products. 
Calcium silicate Wicking action Highly porous, 
light weight 
optimum 
concentration is 
between 20-40% 
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FACTORS AFFECTING DISINTEGRATION 
EFFECT OF FILLERS 
 The solubility and compression characteristics of fillers affect both 
rate and mechanism of disintegration of tablet. If soluble fillers are used 
then it may cause increase in viscosity of the penetrating fluid which tends 
to reduce effectiveness of strongly swelling disintegrating agents and as 
they are water soluble, they are likely to dissolve rather than disintegrate. 
Insoluble diluents produce rapid disintegration with adequate amount of 
disintegrants. Chebli and Cartilier proved that tablets made with spray 
dried lactose (water soluble filler) disintegrate more slowly due to its 
amorphous character and has no solid planes on which the disintegrating 
forces can be exerted than the tablet made with crystalline lactose 
monohydrate. 
 
EFFECT OF BINDER 
 As binding capacity of the binder increases, disintegrating time of 
tablet increases and this counteract the rapid disintegration. Even the 
concentration of the binder can also affect the disintegration time of tablet. 
 
EFFECT OF LUBRICANTS 
 Mostly lubricants are hydrophobic and they are usually used in 
smaller size than any other ingredient in the tablet formulation. When the 
mixture is mixed, lubricant particles may adhere to the surface of the other 
particles. This hydrophobic coating inhibits the wetting and consequently 
tablet disintegration. Lubricant has a strong negative effect on the water 
uptake if tablet contains no disintegrants or even high concentration of 
slightly swelling disintegrants. On the contrary, the disintegration time is 
hardly affected if there is some strongly swelling disintegrants are present 
in the tablet. But there is one exception like sodium starch glycolate whose 
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effect remains unaffected in the presence of hydrophobic lubricant unlike 
other disintegrants. 
 
EFFECT OF SURFACTANTS 
 Sodium lauryl sulphate increased absorption of water by starch or 
had a variable effect on water penetration in tablets. Surfactants are only 
effective within certain concentration ranges. Surfactants are 
recommended to decrease the hydrophobicity of the drugs because the 
more hydrophobic the tablet the greater the disintegration time.7,8 
 
PREFORMULATION STUDIES 
 It is an investigation of physical and chemical properties of the new 
compound (drug) that could affect drug performance and development of 
an efficacious dosage form. Thus preference is the basis for effective 
formulation and drug stability. 
Major areas of Preformulation Research 
I. Bulk Characterization 
a. Crystallinity and Polymorphism 
b. Hygroscopy 
c. Fine particle characterization 
d. Bulk density 
e. Powder flow properties 
II. Solubility analysis 
a. Ionization constant pKa 
b. pH solubility profile 
c. Common ion effect 
d. Thermal effects 
e. Solubilization 
f. Partition coefficient 
g. Dissolution 
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III. Stability analysis 
a. Stability in toxicology formulations 
b. Solution stability 
c. pH rate profile 
d. Solid state stability 
e. Bulk stability 
f. Compatibility 
 
DERIVED PROPERTIES OF POWDERS 
POROSITY: Influences the dissolution of the drug 
BULK DENSITY: Helps in selecting containers for packing a dosage form 
FLOW PROPERTIES: Helps in maintaining a uniform weight of tablets or 
capsules during production.6 
ANGLE OF REPOSE: Angle of repose was determined by using funnel 
method. The accurately weighted blend was taken in a funnel. The height 
of the funnel was adjusted in such was that the tip of the funnel just 
touches the apex of the heap of blend. The drug excipient blend/granules 
were allowed to follow through the funnel freely on to the surface. The 
diameter of the powder cone was measured and angle of repose was 
calculated using the following equation. 
r
htan =θ  
Where h and r are the height and radius of the powder cone. 
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TABLE NO. 6: ANGLE OF REPOSE 
Angle of repose (θ) Type of flow 
25 - 30 Excellent 
31 – 35 Good 
36 – 40 Fair- aid not needed 
41 – 45 Passable – may hang up 
46 – 55 Poor – must agitate, vibrate 
56 – 65 Very poor 
>66 Very, very poor 
 
BULK DENSITY AND TAPPED DENSITY 
 The bulk density of a solid is often very difficult to measure since 
the slightest disturbance of the bed may result in a new bulk density. 
Moreover, it is clear that the bulking properties of a powder are dependent 
on the “history” of the powder (E.g. How it was handled), and that it can be 
packed to have a range of bulk densities. Thus, it is essential in reporting 
bulk density to specify how the determination was made. 
Because the interparticulate interactions that influence the bulking 
properties of a powder are also the interactions that interfere with powder 
flow, a comparison of the bulk and tapped densities can give a measure of 
the relative importance of these interactions in a given powder to flow. The 
bulk density often is the bulk density of the powder as poured” or as 
passively filled into a measuring vessel. The tapped density is a limiting 
density attained after “tapping down” usually in a device that lifts and drops 
a volumetric measuring cylinder containing the powder a fixed distance. 
 
BULK DENSITY 
 Bulk density is determined by measuring the volume of a known 
mass of powder sample that has been passed through a screen into a 
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graduated cylinder (method I) or through a volume measuring apparatus 
into a cup (method II) 
0V
M  
Where, M = weight of API/granules 
 V0 = unsettled apparent volume 
 
TAPPED DENSITY 
Tapped density is achieved by mechanically tapping a measuring 
cylinder containing a powder sample. After observing the initial volume, 
the cylinder is mechanically tapped and volume readings are taken until 
little further volume change is observed. The mechanical tapping is 
achieved by raising the cylinder and allowing it to drop under its own 
weight a specified distance by either of two methods as described below. 
Devices that rotate the cylinder during tapping may be preferred to 
minimize any possible separation of the mass during tapping down. 
fV
M  
Where, M = Weight of API/ granules, 
 Vf = tapped volume 
 
COMPRESSIBILITY INDEX AND HAUSNER RATIO 
 The compressibility index and Hausner ratio are measures of the 
property of a powder to be compressed. As such, they are measures of 
the relative importance of interparticulate interaction. In a free flowing 
powder, such interactions are generally less significant and the bulk and 
tapped densities will be closer in value. For poorer flowing materials, there 
are frequently grater interparticle interactions and a greater difference 
between the bulk and tapped densities will be observed. These differences 
are reflected in the compressibility and Hausner ratio. 
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 The compressibility index and the closely related Hausner ratio 
become the simple, fast, and popular method of predicting powder flow 
characteristics. The compressibility index has been proposed as an 
indirect measure of bulk density, size and shape, surface area, moisture 
content, and cohesiveness of materials because all of these can influence 
the observed compressibility index. The compressibility index and 
Hausner's ratio are determined by measuring both the bulk volume and 
tapped volume of the powder. 
 
BASIC METHODS FOR COMPRESSIBILITY INDEX AND HAUSNER’S 
RATIO 
 The basic procedure is to measure (1) the unsettled apparent 
volume, V0, and (2) the final tapped volume, Vf, of the powder after tapping 
the material until no further volume change occur. The compressibility 
index and Hausner’s ratio are calculated as follows. 
Compressibility Index = ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −×
0
100
V
VV fo
 
Hausner ratio = 
f
o
V
V  
Alternatively the compressibility index and Hausner ratio may be 
calculated using measured value for bulk density (ρtapped) as follow 
Compressibility Index = ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −×
tapped
Bulktapped
ρ
ρρ
100
 
Hausner ratio = ⎟⎟⎠
⎞
⎜⎜⎝
⎛
Bulk
tapped
ρ
ρ
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TABLE NO. 7: SCALE OF FLOW ABILITY9,10 
Compressibility index (%) Flow character Hausner Ratio 
<10 Excellent 1.00 – 1.11  
11 – 15  Good 1.12 – 1.18  
16 – 20  Fair 1.19 – 1.25  
21 – 25  Passable 1.26 – 1.34  
26 – 31  Poor 1.34 – 1.45  
32 – 37  Very poor 1.46 – 1.59 
>38 Very, Very poor >1.60 
 
 
STABILITY STUDIES 
 The purpose of stability testing is to investigate how the quality of a 
drug product changes with time under the influence of environmental 
factors such as temperature, humidity and light and to establish a shelf life 
for the drug product and to recommend storage conditions. 
Pharmaceutical regulatory agencies world-wide demand that the 
product retains its identity, quality, purity and potency for the time the 
product is commercially available. Consequently, the agencies expected to 
see the stability data supporting the proposed expiration date of the 
product in the marketing submission. 
 Various stability guidelines have been published over the last 5 
years describing the type of studies and type of data needed to satisfy 
regulatory agencies world wide. Currently the guidelines promulgated by 
the International Conference on Harmonization (ICH) are the most 
commonly accepted. In the broadest sense, the stability studies that are 
conducted should provide evidence of how the quality of the drug 
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substance and drug product changes over time when subjected to various 
environmental conditions, such as temperature, humidity and light. 
 Some of the important definitions as per ICH guidelines used to 
facilitate interpretation of the guidelines as follows: 
 
FORMAL STABILITY STUDIES 
 Long term and accelerated (and intermediate) studies undertaken 
on primary and/or commitment batches according to a prescribed stability 
protocol to establish or confirm the re-test period of a drug substance or 
the shelf life of a drug product. 
 
LONG TERM TESTING / REAL TIME TESTING 
 Stability studies under the recommended storage condition for the 
re-test period or shelf life proposed or approved for labeling. 
 
INTERMEDIATE TESTING 
 Studies conducted at 30°C / 65% RH and designed to moderately 
increase the rate of chemical degradation or physical changes for a drug 
substance or drug product intended to be stored long term at 25°C. 
 
ACCELERATED TESTING 
 Studies designed to increase the rate of chemical degradation or 
physical change of a drug substance or drug product by using 
exaggerated storage conditions as part of the formal stability studies. Data 
from these studies, in addition to long term stability studies, can be used to 
assess longer term chemical effects at non-accelerated conditions and to 
evaluate the effect of short term excursions outside the label storage 
conditions such as might occur during shipping. Results from accelerated 
testing studies are not always predictive of physical changes. 
 
Chapter 2  Introduction 
 30
CLIMATIC ZONES 
 The four zones in the world that are distinguished by their 
characteristic prevalent annual climatic conditions. This is based on the 
concept described by W. Grimm. 
 
DOSAGE FORM 
 A pharmaceutical product type (E.g.: tablet, capsule, solution, 
cream) that contains a drug substance generally, but not necessarily, in 
association with excipients. 
 
DRUG PRODUCT 
 The dosage from in the final immediate packaging intended for 
marketing. 
 
DRUG SUBSTANCE 
 The unformulated drug substance that may subsequently be 
formulated with excipients to produce the dosage form. 
 
EXPIRATION DATE 
 The date placed on the container label of a drug product 
designating the time prior to which a batch of the product is expected to 
remain within the approved shelf life specification if stored under defined 
conditions, and after which is must not be used. 
 
NEW DRUG SUBSTANCE 
 The designed therapeutic moiety, which has no previously been 
registered in a region or member state (also referred to as a new 
molecular entity or new chemical entity). It may be a complex, simple 
ester, or salt of a previously approved drug substance. 
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NEW DRUG PRODUCT 
 A pharmaceutical product type, for example, tablet, capsule, 
solution, cream etc., which has not previously been registered in a region 
or member state, and which contains a drug ingredient generally, but not 
necessarily in association with excipients. 
 
DEGRADATION PRODUCT 
 A molecule resulting from a chemical change in the drug molecule 
brought about over time and/or by the action of e.g. light, temperature, pH, 
water, or by reaction with a excipient and/or the immediate 
container/closure system. Also called decomposition product. 
 
IMPURITY 
1) Any component of the new drug substance which is not the 
chemical entity defined as the new drug substance. 
2) Any components of the drug product which is not the chemical 
entity defined as the drug substance or an excipient in the drug 
product. 
 
IMMEDIATE RELEASE 
 Allows the drug to dissolve in the gastrointestinal contents, with the 
intention of delaying or prolonging the dissolution or absorption of the 
drug. 
 In general stability studies are classified into 
1. Real time or long time 
2. Intermediate 
3. Accelerated 
 Based on the place (zone) of study the stability studies are 
selected. 
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TABLE NO. 8: CLIMATIC ZONE AND STORAGE CONDITIONS 
Climate zone Conditions Derived storage condition 
I Temperature 21oC / 45% RH 
II Mediterranean, subtropical 25oC / 45% RH 
III Hot, dry 30oC / 45% RH 
IV Hot, humid 30oC / 45% RH 
 
TABLE NO. 9: TESTING FREQUENCY11,12 
Study Storage condition 
Intervals (months)/minimum time 
period covered by data at submission
Long term 25
oC ± 2oC / 
60% ± 5% RHa 
3, 6, 9, 12, 18, 24, 36 / minimum 12 
months 
Intermediate* 30
oC ± 2oC / 
65% ± 5% RH 6, 9
b, 12b minimum 6 months 
Accelerated 40
oC ± 2oC / 
75%c ± 5% RH 1, 3, 6 / minimum 6 months 
 
* If 30oC ± 2oC / 65% RH ± 5% RH is a long term condition, there is no 
intermediate condition. 
a Zone II, 30oC / 35% RH for Zone III, and 30o C / 70% RH for Zone IV. 
b Test 9 and 12 months only if failure to meet specification at 40oC /75% 
RH or assay is different from initial by greater than 5%. 
c FDA’s generic schedule requires testing at 1, 2 and 3 months. 
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NON STEROIDAL ANTI-INFLAMMATORY DRUGS 
(NSAIDs) - A Brief Review 
The anti-inflammatory, analgesic and anti pyretic drugs are a 
heterogeneous group of compounds often chemically unrelated (although 
most of them are organic acids), which nevertheless share certain 
therapeutic actions and side effects. These are called NSAIDs. 
 
Algesia (pain) 
 Algesia is an ill- defined unpleasant sensation usually evoked by an 
external or internal noxious stimulus. 
Analgesic 
 A drug that selectively relieves pain by acting in the CNS, or on 
peripheral pain mechanism with out altering the consciousness.13 
 
DISCOVERY OF NSAIDs 
The development of the first of the category of what are know as 
the non steroidal anti-inflammatory drugs (NSAIDs) of which Aspirin was 
recognized as progenitor, was Phenylbutazone in 1946 and Indomethacin 
in 1960’s14 and later Etodolac in 1970’s2. Phenylbutazone was initially 
employed as a combination with antipyrine. However, it has greater 
analgesic and anti-inflammatory activity than antipyrine and was the best 
part of 30 years successfully used for arthritic and other painful 
inflammatory conditions. 
 
INTRODUCTION OF INFLAMMATION 
Prostaglandins belong to a group of compounds known as 
eicosanoids. Eicosanoids are breakdown products of the polyunsaturated 
fatty acids (e.g., arachidonic acid) of the plasmalemmal phospholipids. 
When cell membranes are damaged, arachidonic acid is liberated into the 
cytoplasm where it serves as a substrate for the lipoxygenases (e.g., 5-
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lipoxygenase), cyclooxygenases (e.g., prostaglandin synthase, 
prostaglandin H (synthase), and other enzymes [Figure No. 5]. 
 
FIGURE NO. 5: SCHEMATIC DEPICTING THE ROLES OF 
CYCLOOXYGENASE (COX)-1, COX-2, AND LIPOXYGENASE (LOX) IN 
THE LIBERATION OF INFLAMMATORY MEDIATORS VIA THE 
ARACHIDONIC ACID CASCADE. 
Although there are three mammalian lipoxygenases, the one with 
the most clinical significance is 5-lipoxygenase. It is 5-lipoxygenase that is 
responsible for the conversion of arachidonic acid to  
5-hydroperoxyeicosatetraenoicacid, which is then enzymatically converted 
to leukotriene A4 (LTA4). Leukotriene A4 is the precursor molecule for the 
other leukotrienes and can be enzymatically converted to leukotriene B4 
(LTB4), which attracts many cells of myeloid origin. Cyclooxygenase 1-
related prostaglandins (i.e., constitutive prostaglandins) are produced by 
many tissues and participate in the maintenance of a variety of 
physiological effects (e.g., protection of gastrointestinal [GI] mucosa, 
maintenance of renal blood flow, hemostasis). Cyclooxygenase 2, on the 
other hand, is the isoform primarily responsible for the production of 
inducible prostaglandins [Figure No. 5]. 
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As such, COX-2-related prostaglandins are considered to be 
“nonphysiologic” and represent a clinically and therapeutically relevant 
group of compounds primarily involved in inflammation. Vasodilatation, 
changes in capillary permeability, potentiation of other chemical mediators 
of inflammation (e.g., histamine), chemotaxis, and hyperalgesia are all 
aspects of inflammation that are initiated and perpetuated by the presence 
of COX-2-related prostaglandins. It is important to note that COX-1 and 
COX-2 are also structurally distinct. They have different numbers of amino 
acids and sequences, as well as different morphologies. A smaller valine 
at the 523 position of COX-2 gives access to a “side pocket” unique to 
COX-2. This side pocket is exploited as the binding site for NSAIDs that 
preferentially bind with COX-2. 
 
MECHANISMS OF ACTION OF NSAIDs 
Nonsteroidal anti-inflammatory drugs block the production of 
prostaglandin by binding to and obstructing the action of cyclooxygenase, 
an interaction that is contingent upon both the drug and dose chosen. The 
therapeutic, toxic, and anti-inflammatory properties of different NSAIDs are 
directly related to the amount and type of prostaglandin production that is 
impeded. Based on the nature and physiological actions of COX-1 and 
COX-2, the NSAIDs that preferentially block the production of COX-2-
related prostaglandins may be clinically superior to those with less COX-2 
selectivity. Nonsteroidal anti-inflammatory drugs that inhibit COX-2 may be 
more desirable, because they inhibit the formation of COX-2 
prostaglandins that are responsible for the clinical signs associated with 
inflammation, and because they do not have as much effect on the COX-1 
prostaglandins, which have many heomostatic properties. The specificity 
of a drug for a given isoform of COX is typically reported as a ratio. A 
COX-2:COX-1 ratio <1.0 has traditionally been sought, as this ratio 
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indicates that a given NSAID preferentially inhibits COX-2 (i.e., less drug is 
required to inhibit COX-2 than is needed to inhibit COX-1 activity).15 
 
CLASSIFICATION OF NSAIDs13 
The various analgesic-antipyretic anti-inflammatory agents are 
classified as 
1. Acidic Drugs  
o Salicylates: E.g. Salicylic acid, Aspirin. 
o Para-amino phenols: E.g.: Paracetamol. 
o Pyrazolones: E.g.: Phenylbutazone, Suxibuzone. 
o Indole acetic acids: E.g.: Indomethacin, Clamidoxic acid. 
o Propionic acids: E.g.: Ibuprofen, Diclofenac. 
o Aryl anthranilic acids: E.g.: Meclofenamic acid, Tolfenamic acid. 
o Miscellaneous agents: E.g.: Piroxicam, Fenoxicam. 
2. Basic Drugs E.g.: Timegadine inhibits neutrophil degranulation and 
superoxide production. 
3. Non-Acidic Drugs E.g.: Indoxole Nictimodole. 
 
CLASSIFICATION OF NSAIDs BY CHEMICAL STRUCTURE 
1. Carboxylic Acid Groups 
o Salicylates (Acetylsalicylate, Choline Salicylate, Diflunisal, 
Magnesium choline Salicylate, Magnesium Salicylate, 
Salsalate). 
o Acetic Acids (Diclofenac Sodium, Diclofenac Potassium, 
Etodolac, Indomethacin, Ketorolac, Nabumetone, Sulindac, 
Tolmetin). 
o Propionic acids (Carprofen, Fenoprofen, Flurbiprofen, Ibuprofen, 
Ketoprofen, Loxoprofen, Naproxen, Naproxen sodium, 
Oxaprozin, Vedaprofen). 
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o Anthranilic acids (Meclofenamic acid, Meclofenamate sodium, 
Tolfenamic acid). 
o Phenlylacetic acids (Acetaminophen). 
o Amino nicotinic acids (Flunixin). 
o Indole Analogs (Indomethacin, Nabumetone, Ketorolac, 
Etodolac). 
2. Enolic Acid Groups (which doesn't have carboxylic group but acid 
due to the enolic Hydroxyl substituent): 
o Pyrazolones (Phenylbutazone, Oxyphenbutazone, Dipyrone, 
Ramifenazone). 
o Oxicams (Aceclofenac, Piroxicam, Tenoxicam). 
3. Coxibs Celecoxib, Rofecoxib, Valdecoxib, Parecoxib, Etoricoxib. 
4. Gold Salts Auranofin, Gold sodium thiomalate, Aurothioglucose. 
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TABLE NO. 10: SIDE EFFECTS OF NON-STEROIDAL  
ANTI-INFLAMMATORY DRUGS (NSAIDS)16 
Serious side effects include Other side effects 
include 
• heart attack 
• stroke 
• high blood pressure 
• heart failure from body swelling (fluid retention) 
• kidney problems including kidney failure 
• bleeding and ulcers in the stomach and intestine 
• low red blood cells (anemia) 
• life-threatening skin reactions 
• life-threatening allergic reactions 
• liver problems including liver failure 
• asthma attacks in people who have asthma 
• constipation 
• stomach pain 
• diarrhea 
• gas 
• heartburn 
• nausea 
• vomiting 
• dizziness 
 
Get emergency help right away if you have any of the following 
symptoms: 
• shortness of breath or trouble 
breathing 
• chest pain 
• slurred speech 
• swelling of the face or throat 
 
Stop your NSAID medicine and call your healthcare provider right 
away if you have any of the following symptoms: 
• nausea 
• more tired or weaker than usual 
• itching 
• your skin or eyes look yellow 
• stomach pain 
• flu-like symptoms 
• vomit blood 
• there is blood in your bowel 
movement or it is black and 
sticky like tar 
• unusual weight gain 
• skin rash or blisters with fever 
• swelling of the arms and legs, 
hands and feet 
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TABLE NO. 11: NSAID MEDICINES THAT NEED A PRESCRIPTION16 
Generic Name Trade name 
Diclofenac Cataflam, Voltaren, Arthrotec (combined with 
misoprostol) 
Diflunisal Dolobid 
Etodolac Lodine, Lodine XL 
Fenoprofen Nalfon, Nalfon 200 
Flurbiprofen Ansaid 
Ibuprofen Motrin, Tab-Profen, Vicoprofen (combined with 
hydrocodone), Combunox 
Indomethacin Indocin, Indocin SR, Indo-Lemmon, Indomethagan 
Ketoprofen Oruvail 
Ketorolac Toradol 
Mefenamic Acid Ponstel 
Meloxicam Mobic 
Nabumetone Relafen 
Naproxen Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, 
Naprelan, Naprapac 
Oxaprozin Daypro 
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DRUG PROFILE 
 
ETODOLAC2,17 
 Etodolac is a member of the pyranocarboxylic acid group of Non 
Steroidal Anti-Inflammatory Drug (NSAID). Etodolac is a racemic mixture 
of [+] S and [-] R-enantiomers. 
CHEMICAL NAME: (±) 1, 8-diethyl-1, 3, 4, 9,-tetrahydropyrano-[3,4-
b]indole-1-acetic acid. 
NONPROPRIETARY NAMES / SYNONYMS: Etodolac, Etodolic acid, 
Etodolaco; Etodolacum; Etodolák; Etodolak; Etodolaakki; Etodolakas. 
PROPRIETARY NAMES: Lodine, Ramodar, Ultradol, Zedolac, Edolan. 
EMPIRICAL FORMULA: C17H21NO3. 
MOLECULAR WEIGHT: 287.37. 
CAS NUMBER: 41340-25-4. 
MELTING POINT: 144°C to 150°C. 
pKa AND n-OCTANOL:WATER PARTITION COEFFICIENT: 4.65 and 
11.4 at pH 7.4. 
CHEMICAL STRUCTURE: 
 
ELEMENTAL ANALYSIS: The calculated elemental composition is as 
follows 
Carbon: 71.06%, Oxygen: 16.70%, Hydrogen: 7.37%, Nitrogen: 4.87% 
DESCRIPTION: Etodolac is a white crystalline compound, insoluble in 
water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous 
polyethylene glycol. 
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INDICATIONS: Analgesic; anti-inflammatory; antipyretic.  
 
PREPARATIONS AVAILABLE WORLDWIDE FOR ETODOLAC16 
TABLE NO. 12: PREPARATIONS AVAILABLE WORLDWIDE FOR 
ETODOLAC 
Brand Name Company Name Country Name 
Eccoxolac Viatris United Kingdom 
Etonox Charoen Thailand 
Flancox Apsen Brazil 
Lodine Sankyo France 
Lodine Wyeth Hong Kong 
Lodine Wyeth Venezuela 
Lodine Wyeth Lederle Italy 
Lonene Sunthi Sepuri Indonesia 
Sodolac Sofex Portugal 
Ultradol Procter and Gamble Canada 
Ecridoxan Help Germany 
Etopan Taro Israel 
Hypen Shinyaku Japan 
Lodine Shire United Kingdom 
Lodine Wyeth Mexico 
Lodine Wyeth-Ayerst USA 
Lodine Wyeth LederlePort. USA 
Lonine Wyeth Germany 
Tadolak Saba Turkey 
Zedolac Maggioni Italy 
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Brand Name Company Name Country Name 
Edolan Lepetit Italy 
Etol Nobel Turkey 
Etopan Winthrop United Kingdom 
Lodine Algol Finland 
Lodine Sigma-Tau Switzerland 
Lodine Wyeth Turkey 
Lodine Wyeth Lederle Austria 
Lodot BA Farma Portugal 
Metazin Clintex Portugal 
Todolac Norpharma Denmark 
Dualgan ITF Portugal 
 
 
PHARMACOKINETICS 
ABSORPTION 
¾ Onset and Duration of action 
 Onset of action: 
 Initial response – Analgesia, Regular release is 30 minutes. 
 Peak response – Analgesia, Regular release is 1 to 2 hours. 
 Duration of action: 
 Single dose – Analgesia, Regular release is 4 to 5 hours. 
¾ Drug Concentration levels 
 Time to Peak Concentration:  
 Oral, Regular release is 1 to 2 hours. 
 Oral, Extended release is 3 to 12 hours. 
Peak Concentration are dose-proportional for both free and total 
Etodolac following 400 mg every 12 hours, following 600 mg, the peak 
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is  approximately 20% higher than expected on the basis of the lower 
doses. 
¾ Bioavailability 
 Oral, Regular release is 80% to 100%. 
 Oral, Extended release is 78% to 84%. 
¾ Effects of Food 
Clinically significant: 
 The peak concentration is 50% and the time to reach peak 
concentration is increased by about 1.4 to 3.8 hours. 
 When Etodolac extended-release is administered with food, 
peak serum concentrations occurs earlier at 1.5 to 6 hours. 
 High-fat meals do not affect the absorption of Etodolac 
extended-release. 
 
DISTRIBUTION 
¾ Distribution sites: Protein Binding - 99% 
¾ Distribution Kinetics 
 Distribution Half-Life – 0.71 hours. 
 Volume of distribution – 362 ml/kg, Etodolac exhibit two 
compartment pharmacokinetics, the Vd of the central 
compartment is 132 ml/kg. 
 
METABOLISM 
¾ Metabolism Sites and Kinetics: Liver, extensive. 
¾ Metabolism: 
 Glucuronide metabolite, inactive. 
 Hydroxylated metabolite, inactive. 
 Glucuronidated hydroxylated metabolite, inactive. 
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EXCRETION 
¾ Kidney 
 Renal Excretion (%) – 72 %. 
 About 1% of a dose is excreted as unchanged drug, the 
remainder is excreted as metabolites. 
¾ Others: Feces, 16% 
¾ Elimination Half-life: 6 to 7 hours. 
 
DOSING INFORMATION 
¾ Osteoarthritis 
 Initial: Immediate release, 300 mg orally two or three 
times day or 400 to 500 mg orally two times a day. 
 Maintenance: Extended release, 400 to 1000 mg orally 
once a day, immediate release, 600 to 1000 mg/day 
orally divided 2 to 4 times maximum dose 1200 mg/day. 
¾ Pain 
 Immediate release, 200 to 400 mg orally every 6 to 8 hours 
as needed, maximum dose 1200 mg/day. 
¾ Rheumatoid Arthritis 
 Initial: Immediate Release, 300 mg orally two or three times 
a day or 400 to 500 mg orally two times a day. 
 Maintenance: Extended Release, 400-1000 mg orally once a 
day. Immediate Release, 600-1000 mg/day orally divided 2-
4 times. Maximum dose 1200 mg/day. 
¾ Adults 
 Use lowest effective dose for shortest possible duration. 
 After observing initial response, adjust dose and frequency to 
meet individual patient’s needs. 
¾ Pediatrics 
 Not FDA approved for children less than 6 years old. 
Chapter 3  Drug Profile 
 
 45
 Use lowest effective dose for shortest possible duration. 
 After observing initial response, adjust dose and frequency to 
meet individual patient’s needs. 
 
DOSAGE IN RENAL FAILURE: No dosage adjustment of Etodolac is 
necessary in patients with mild-to-moderate renal failure. However, 
Etodolac should be used with caution because it may cause cumulative 
effects on renal function especially in patients with pre-existing mild-to-
moderate renal dysfunction. 
 
DOSAGE IN HEPATIC INSUFFICIENCY: In patients with compensated 
hepatic cirrhosis, the dose of Etodolac does not need to be adjusted. 
However, the dose may need to be decreased in patients with severe 
hepatic failure. 
 
DOSAGE IN GERIATRIC PATIENTS: The dose of Etodolac does not 
need to be adjusted in elderly patients; however, it should be used 
cautiously since the elderly are more sensitive to the side effects. 
 
CONTRAINDICATIONS 
 Treatment of pre-operative pain in setting of coronary artery 
bypass graft (CABG) surgery. 
 Hypersensitivity to Etodolac. 
 Patients who have experienced asthma, urticaria, or allergic-
type reactions after taking aspirin or other nonsteroidal anti-
inflammatory agents; severe, even fatal, anaphylactic-like 
reactions have been reported. 
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TABLE NO. 13: ADVERSE EFFECTS OF ETODOLAC 
Serious side effects include Other side effects include 
Heart attack, Stroke, High blood 
pressure, Heart failure from body 
swelling(fluid retention), kidney 
problems, Bleeding and Ulcer in the 
stomach and intestine, Low red 
blood cells(anemia), Shortness of 
breath or trouble breathing, Chest 
pain, Weakness in one part or side 
of your body, flu- like symptoms. 
Stomach pain, Constipation, 
Diarrhea, Slurred speech, Swelling 
of the face or throat, unusual 
weight gain, skin rash or blisters 
with fever, Skin rash or blisters with 
fever, swelling of the arms and 
legs, hands and feet 
 
DRUG INTERACTIONS 
ACE-INHIBITORS 
 • Alacepril - Interaction Effect is decreased Antihypertensive and 
natriuretic effects and probable mechanism is interference with 
production of vasodilator and natriuretic prostaglandins. 
ASPIRIN 
 When Etodolac is administered with aspirin, its protein binding is 
reduced, although the clearance of free Etodolac is not altered. The 
clinical significance of this interaction is not known; however, as with other 
NSAIDs, concomitant administration of Etodolac and aspirin is not 
generally recommended because of the potential of increased adverse 
effects. 
ANTACIDS 
 The concomitant administration of antacids has no apparent effect 
on the extent of absorption of Etodolac. However, antacids can decrease 
the peak concentration reached by 15% to 20% but have no detectable 
effect on the time-to-peak. 
DIURETICS 
 Etodolac has no apparent pharmacokinetic interaction when 
administered with furosemide or hydrochlorothiazide. Nevertheless, clinical 
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studies, as well as post marketing observations have shown that Etodolac 
can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal 
prostaglandin synthesis. During concomitant therapy with NSAIDs, the 
patient should be observed closely for signs of renal failure. 
GLYBURIDE 
 Etodolac has no apparent pharmacokinetic interaction when 
administered with glyburide. 
LITHIUM 
 NSAIDs have produced an elevation of plasma lithium levels and a 
reduction in renal lithium clearance. The mean minimum lithium 
concentration increased 15% and the renal clearance was decreased by 
approximately 20%. These effects have been attributed to inhibition of 
renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and 
lithium are administered concurrently, subjects should be observed 
carefully for signs of lithium toxicity. 
PHENYLBUTAZONE 
 Phenylbutazone causes increase (by about 80%) in the free fraction 
of Etodolac. Although in vivo studies have not been done to see if 
Etodolac clearance is changed by co-administration of phenylbutazone, it 
is not recommended that they be co administered. 
PHENYTOIN 
 Etodolac has no apparent pharmacokinetic interaction when 
administered with phenytoin. 
WARFARIN 
 The effects of warfarin and NSAIDs on GI bleeding are synergistic, 
such that users of both drugs together have a risk of serious GI bleeding 
higher than that of users of either drug alone. Short-term pharmacokinetic 
studies have demonstrated that concomitant administration of warfarin and 
Lodine® (Etodolac capsules and tablets) results in reduced protein binding 
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of warfarin, but there was no change in the clearance of free warfarin. 
There was no significant difference in the pharmacodynamic effect of 
warfarin administered alone and warfarin administered with Etodolac as 
measured by prothrombin time. Thus, concomitant therapy with warfarin 
and Etodolac should not require dosage adjustment of either drug. 
However, caution should be exercised because there have been a few 
spontaneous reports of prolonged prothrombin times, with or without 
bleeding, in Etodolac-treated patients receiving concomitant warfarin 
therapy. 
CYCLOSPORINE, DIGOXIN, METHOTREXATE 
 Etodolac, like other NSAIDs, through effects on renal 
prostaglandins, may cause changes in the elimination of these drugs 
leading to elevated serum levels of cyclosporine, digoxin, methotrexate, 
and increased toxicity. Nephrotoxicity associated with cyclosporine may 
also be enhanced. Patients receiving these drugs who are given Etodolac, 
or any other NSAID, and particularly those patients with altered renal 
function, should be observed for the development of the specific toxicities 
of these drugs. NSAIDs have been reported to competitively inhibit 
methotrexate accumulation in rabbit kidney slices. This may indicate that 
they could enhance the toxicity of methotrexate. Caution should be used 
when NSAIDs are administered concomitantly with methotrexate. 
 
SAFETY PROFILE OF ETODOLAC 
¾ Etodolac is a nonsteroidal anti-inflammatory drug (NSAIDs) of the 
pyranocarboxylic acid class developed in the 1970s.2 
¾ Etodolac is a synthesized anti-inflammatory drug with potent 
inhibitory activity against interleukin-1 beta (IL-1beta)-induced 
prostaglandin E2 biosynthesis in chondrocytes. 
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¾ Since gastrointestinal (GI) complaints and blood loss are frequently 
associated with the use of anti-inflammatory agents, several studies 
have been conducted to assess the effect of Etodolac on the GIT. 
¾  The pharmacological activities and ulcerogenicity of Etodolac 
compare with six other nonsteroidal anti-inflammatory drugs: 
Indomethacin, Diclofenac Sodium, Piroxicam, Naproxen, 
Ketoprofen and Aspirin.  
¾ The safety margin of Etodolac was calculated from ED50 value for 
the primary inflammation of adjuvant arthritis, the ED50 value for the 
secondary inflammation of adjuvant arthritis and the acetic acid 
induced writhing were highest among the 7 drugs. These results 
indicate that safety margins for Etodolac are high. 
¾ The ulcerogenic action of the anti-inflammatory drugs is due to the 
inhibition of prostaglandin biosynthesis in the stomach. Etodolac 
showed the lowest ulcerogenicity among the 7 drugs tested.  
¾ This weak ulcerogenic activity may be derived from the weak 
inhibitory activity of Etodolac on prostaglandin biosynthesis in the 
gastric mucosa. 
¾ These results suggest that Etodolac is useful in the clinical 
treatment of rheumatoid arthritis. Etodolac did not show an 
analgesic effect on non-inflammatory pain in the normal paws of 
rats and an antipyretic effect on the rectal temperature of normal 
rats. 
¾ Etodolac is considered, overall, to be an anti-inflammatory drug with 
potent antiarthritic activity and weak ulcerogenic activity.4 
¾ As a COX-2 selective inhibitor, Etodolac can not only enhance its 
anti-inflammatory and analgesic activity but also improve patient 
compliance.18 
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¾ Etodolac, with an effective anti-inflammatory dose, no sustained 
effects on renal function were found in either normal or renal-
impaired patients.19 
¾ The most frequently used NSAIDs are shown in descending order 
in Figure No. 6.20 
 
FIGURE NO. 6: RATIO OF PRESCRIPTION OF COMMON 
NSAIDS 
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EXCIPIENT PROFILE21 
 
CROSPOVIDONE 
NONPROPRIETARY NAMES  
• BP : Crospovidone 
• PhEur : Crospovidonum 
• USPNF : Crospovidone 
 
SYNONYMS: Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; 
Polyplasdone XL; Polyplasdone XL-10; Polyvinylpolypyrrolidone; PVPP;  
CHEMICAL NAME AND CAS REGISTRY NUMBER: 1-ethenyl-2-
pyrrolidinone homopolymer [9003-39-8] 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: (C6H9NO)n 
>1 000 000. 
STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY: Tablet Disintegrant. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Crospovidone 
is a water-insoluble tablet disintegrant and dissolution agent used at 2–5% 
concentration in tablets prepared by direct-compression or wet- and dry-
granulation methods. It rapidly exhibits high capillary activity and 
pronounced hydration capacity, with little tendency to form gels. Studies 
suggest that the particle size of crospovidone strongly influences 
disintegration of analgesic tablets. Larger particles provide a faster 
disintegration than smaller particles. Crospovidone can also be used as a 
solubility enhancer. With the technique of co-evaporation, crospovidone 
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can be used to enhance the solubility of poorly soluble drugs. The drug is 
adsorbed on to crospovidone in the presence of a suitable solvent and the 
solvent is then evaporated. This technique results in faster dissolution rate. 
DESCRIPTION: Crospovidone is a white to creamy-white, finely divided, 
free-flowing, practically tasteless, odorless or nearly odorless, hygroscopic 
powder. 
TYPICAL PROPERTIES: 
Solubility: Practically insoluble in water and most common organic 
solvents. 
STABILITY AND STORAGE CONDITIONS: Since crospovidone is 
hygroscopic, it should be stored in an airtight container in a cool, dry place. 
INCOMPATIBILITIES: Crospovidone is compatible with most organic and 
inorganic pharmaceutical ingredients. When exposed to a high water level, 
crospovidone may form molecular adduct with some materials. 
SAFETY: Crospovidone is used in oral pharmaceutical formulations and is 
generally regarded as a nontoxic and nonirritant material. Short-term 
animal toxicity studies have shown no adverse effects associated with 
crospovidone. However, owing to the lack of available data, an acceptable 
daily intake in humans has not been specified by the WHO. 
LD50 (mouse, IP): 12 g/kg 
HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Eye protection, 
gloves, and a dust mask are recommended. 
 
SODIUM STARCH GLYCOLATE 
NONPROPRIETARY NAMES 
• BP : Sodium starch glycollate 
• PhEur : Carboxymethylamylum natricum 
• USPNF : Sodium starch glycolate 
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SYNONYMS: Carboxymethyl starch, Sodium salt; Explosol; Explotab; 
Glycolys; Primojel; starch carboxymethyl ether, sodium salt.  
CHEMICAL NAME AND CAS REGISTRY NUMBER: Sodium 
carboxymethyl starch [9063-38-1] 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
The molecular weight is typically 5 × 105–1 × 106. 
STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY: Tablet and Capsule Disintegrant. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Sodium starch 
glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared 
by either direct-compression or wet-granulation processes. The usual 
concentration employed in a formulation is between 2% and 8%, with the 
optimum concentration about 4%, although in many cases 2% is sufficient. 
Sodium starch glycolate has also been investigated for use as a 
suspending vehicle. 
DESCRIPTION: Sodium starch glycolate is a white to off-white, odorless, 
tasteless, free-flowing powder. The PhEur 2005 states that it consists of 
oval or spherical granules, 30–100 µm in diameter, with some less-
spherical granules ranging from 10–35 µm in diameter. 
TYPICAL PROPERTIES: Solubility: Sparingly soluble in ethanol (95%); 
practically insoluble in water. At a concentration of 2% w/v sodium starch 
glycolate disperses in cold water and settles in the form of a highly 
hydrated layer. 
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STABILITY AND STORAGE CONDITIONS: Sodium starch glycolate is 
stable and should be stored in a well-closed container in order to protect it 
from wide variations of humidity and temperature, which may cause 
caking. The physical properties of sodium starch glycolate remain 
unchanged for up to 3–5 years if it is stored at moderate temperatures and 
humidity. 
INCOMPATIBILITIES: Sodium starch glycolate is incompatible with 
ascorbic acid. 
SAFETY: Sodium starch glycolate is widely used in oral pharmaceutical 
formulations and is generally regarded as a nontoxic and nonirritant 
material. However, oral ingestion of large quantities may be harmful. 
HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Sodium starch 
glycolate may be irritant to the eyes; eye protection and gloves are 
recommended. A dust mask or respirator is recommended for processes 
that generate a large quantity of dust. 
 
MICROCRYSTALLINE CELLULOSE 
NONPROPRIETARY NAMES 
• BP : Microcrystalline cellulose 
• JP : Microcrystalline cellulose 
• PhEur : Cellulosum microcristallinum 
• USPNF : Microcrystalline cellulose 
SYNONYMS: Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; 
crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; 
Tabulose; Vivapur. 
CHEMICAL NAME AND CAS REGISTRY NUMBER: Cellulose [9004-34-6] 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: (C6H10O5)n 
≈36 000. where n ≈ 220. 
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STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY: Adsorbent; Suspending agent; Tablet and 
Capsule Diluent; Tablet Disintegrant. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in 
both wet-granulation and direct-compression processes. In addition to its 
use as a binder/diluent, microcrystalline cellulose also has some lubricant 
and disintegrant properties that make it useful in tableting. Microcrystalline 
cellulose is also used in cosmetics and food products 
 
Table No. 14: Uses of microcrystalline cellulose. 
Use Concentration (%) 
Adsorbent 20–90 
Antiadherent 5–20 
Capsule binder/diluent 20–90 
Tablet disintegrant 5–15 
Tablet binder/diluent 20–90 
 
DESCRIPTION: Microcrystalline cellulose is purified, partially 
depolymerized cellulose that occurs as a white, odorless, tasteless, 
crystalline powder composed of porous particles. It is commercially 
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available in different particle sizes and moisture grades that have different 
properties and applications. 
TYPICAL PROPERTIES: 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; 
practically insoluble in water, dilute acids, and most organic solvents. 
STABILITY AND STORAGE CONDITIONS: Microcrystalline cellulose is a 
stable though hygroscopic material. The bulk material should be stored in 
a well-closed container in a cool, dry place. 
INCOMPATIBILITIES: Microcrystalline cellulose is incompatible with 
strong oxidizing agents. 
SAFETY: Microcrystalline cellulose is not absorbed systemically following 
oral administration and thus has little toxic potential. Consumption of large 
quantities of cellulose may have a laxative effect, although this is unlikely 
to be a problem when cellulose is used as an excipient in pharmaceutical 
formulations. Deliberate abuse of formulations containing cellulose, either 
by inhalation or by injection, has resulted in the formation of cellulose 
granulomas. 
 
POVIDONE 
NONPROPRIETARY NAMES 
• BP : Povidone 
• JP : Povidone 
• PhEur : Povidonum 
• USP : Povidone 
 
SYNONYMS: E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-
pyrrolidinyl)ethylene]; Polyvidone; Polyvinylpyrrolidone; PVP; 1-vinyl-2-
pyrrolidinone polymer. 
CHEMICAL NAME AND CAS REGISTRY NUMBER: 1-Ethenyl-2-
pyrrolidinone homopolymer [9003-39-8] 
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EMPIRICAL FORMULA AND MOLECULAR WEIGHT: (C6H9NO)n 2500–
3 000 000 
STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY: Disintegrant; Dissolution Aid; Suspending 
Agent; Tablet Binder. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: In tableting, 
povidone solutions are used as binders in wet-granulation processes. 
Povidone is also added to powder blends in the dry form and granulated in 
situ by the addition of water, alcohol, or hydroalcoholic solutions. Povidone 
is used as a solubilizer in oral and parenteral formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid-dosage 
forms. Povidone solutions may also be used as coating agents. Povidone 
is additionally used as a suspending, stabilizing, or viscosity-increasing 
agent in a number of topical and oral suspensions and solutions. The 
solubility of a number of poorly soluble active drugs may be increased by 
mixing with povidone. 
TABLE NO. 15: USES OF POVIDONE 
Use Concentration (%) 
Carrier for drugs 10–25 
Dispersing agent Up to 5 
Eye drops 2–10 
Suspending agent Up to 5 
Tablet binder, tablet diluent, or coating agent 0.5–5 
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DESCRIPTION: Povidone occurs as a fine, white to creamy-white colored, 
odorless or almost odorless, hygroscopic powder. 
TYPICAL PROPERTIES: Solubility: Freely soluble in acids, chloroform, 
ethanol (95%), ketones, methanol, and water; practically insoluble in ether, 
hydrocarbons, and mineral oil. In water, the concentration of a solution is 
limited only by the viscosity of the resulting solution, which is a function of 
the K-value. 
STABILITY AND STORAGE CONDITIONS: Povidone darkens to some 
extent on heating at 150°C, with a reduction in aqueous solubility. 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, 
it should be stored in an airtight container in a cool, dry place. 
INCOMPATIBILITIES: Povidone is compatible in solution with a wide 
range of inorganic salts, natural and synthetic resins, and other chemicals. 
It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, phenobarbital, tannin, and other compounds. The efficacy of 
some preservatives, e.g. thimerosal, may be adversely affected by the 
formation of complexes with povidone. 
SAFETY: Povidone has been used in pharmaceutical formulations for 
many years, being first used in the 1940s as a plasma expander, although 
it has now been superseded for this purpose by dextran.Povidone is 
widely used as an excipient, particularly in oral tablets and solutions. 
When consumed orally, povidone may be regarded as essentially nontoxic 
since it is not absorbed from the gastrointestinal tract or mucous 
membranes. Povidone additionally has no irritant effect on the skin and 
causes no sensitization. 
 A temporary acceptable daily intake for povidone has been set by 
the WHO at up to 25 mg/kg body-weight. 
LD50 (mouse, IP): 12 g/kg 
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HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Eye protection, 
gloves, and a dust mask are recommended. 
 
POLYOXYETHYLENE SORBITAN FATTY ACID ESTERS 
NONPROPRIETARY NAMES 
• BP : Polysorbate 20, Polysorbate 40, 
Polysorbate 60, and Polysorbate 80 
• JP : Polysorbate 80 
• PhEur : Polysorbatum 20, Polysorbatum 40, 
Polysorbatum 60, Polysorbatum 80 
• USPNF : Polysorbate 20, Polysorbate 40, 
Polysorbate 60, and Polysorbate 80 
SYNONYMS: 
TABLE NO. 16: SYNONYMS OF SELECTED POLYSORBATES  
POLYSORBATE SYNONYMS 
Polysorbate 20 Armotan PML 20; Capmul POE-L; Crillet 1; Drewmulse; 
E432; Durfax 20; Lamesorb SML-20; Liposorb L-20; 
Montanox 20; Norfox Sorbo T-20; sorbitan 
monododecanoate; Sorgen TW-20; T-Maz 20; 
polyoxyethylene 20 laurate; Protasorb L-20; Tween 20. 
Polysorbate 40 Crillet 2; E434; Eumulgin SMP; Glycosperse S-20;; 
Lamesorb SMP-20; Liposorb P-20; Lonzest SMP-20; 
Montanox 40; Protasorb P-20; Ritabate 40; sorbitan 
monohexadecanoate; Sorbax PMP-20; Tween 40. 
Polysorbate 60 Atlas 70K; Atlas Armotan PMS 20; Capmul POE-S; 
Crillet 3; Drewpone 60K; Durfax 60; Montanox 60; 
Polycon T 60 K; polyoxyethylene 20 stearate; Ritabate 
60; Protasorb S-20; Sorbax PMS-20; T-Max 60KHS; 
Tween 60; Tween 60K; Tween 60. 
Polysorbate 80 Atlas E; Armotan PMO 20; Capmul POE-O; Cremophor 
PS 80; Crillet 4; Crillet 50; Drewmulse POE-SMO; 
Drewpone 80K; Durfax 80; Durfax 80K; E433; Emrite 
6120; Eumulgin SMO; Glycosperse O-20; Hodag 
PSMO-20; Liposorb O-20; Montanox 80; 
polyoxyethylene 20 oleate; -20; Tween 80. 
 
Chapter 4  Excipient Profile 
 60
CHEMICAL NAMES AND CAS REGISTRY NUMBERS 
TABLE NO. 17: CHEMICAL NAMES AND CAS REGISTRY NUMBERS 
OF SELECTED POLYSORBATES 
Polysorbate Chemical name CAS number 
Polysorbate 20 Polyoxyethylene 20 sorbitan 
monolaurate 
[9005-64-5] 
Polysorbate 40 Polyoxyethylene 20 sorbitan 
monopalmitate 
[9005-66-7] 
Polysorbate 60 Polyoxyethylene 20 sorbitan 
monostearate 
[9005-67-8] 
Polysorbate 80 Polyoxyethylene 20 sorbitan 
monooleate 
[9005-65-6] 
 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
TABLE NO. 18: EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
OF SELECTED POLYSORBATES 
Polysorbate Formula Molecular weight 
Polysorbate 20 C58H114O26 1128 
Polysorbate 40 C62H122O26 1284 
Polysorbate 60 C64H126O26 1312 
Polysorbate 80 C64H124O26 1310 
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STRUCTURAL FORMULA 
  
FUNCTIONAL CATEGORY: Emulsifying agent; Nonionic Surfactant; 
Solubilizing Agent; Wetting and Suspending agent. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Polysorbates 
may also be used as solubilizing agents for a variety of substances 
including essential oils and oil-soluble vitamins, and as wetting agents in 
the formulation of oral and parenteral suspensions. They have been found 
to be useful in improving the oral bioavailability of drug molecules that are 
substrates for p-glycoprotein. Polysorbates are also widely used in 
cosmetics and food products. 
TABLE NO. 19: USES OF POLYSORBATES 
Use Concentration (%) 
Emulsifying agent  
Used alone in oil-in-water emulsions 1–15 
Used in combination with hydrophilic emulsifiers in 
oil-in-water emulsions 
1–10 
Used to increase the water-holding properties of 
ointments 
1–10 
Solubilizing agent  
Wetting agent  
 
DESCRIPTION: Polysorbates have a characteristic odor and a warm, 
somewhat bitter taste. 
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TABLE NO. 20: COLORS AND PHYSICAL FORMS OF 
POLYSORBATES AT 25°C 
Polysorbate Color and form at 25°C 
Polysorbate 20 Yellow oily liquid 
Polysorbate 40 Yellow oily liquid 
Polysorbate 60 Yellow oily liquid 
Polysorbate 80 Yellow oily liquid 
 
TYPICAL PROPERTIES: 
Solubility: 
TABLE NO. 21: SOLUBILITY OF SELECTED POLYSORBATES IN 
VARIOUS SOLVENTS 
Solvent 
Polysorbate 
Ethanol Mineral oil Vegetable oil Water 
Polysorbate 20 S I I S 
Polysorbate 40 S I I S 
Polysorbate 60 S I I S 
Polysorbate 80 S I I S 
D = dispersible; I = insoluble; S = soluble; T = turbid; W = on warming. 
STABILITY AND STORAGE CONDITIONS: Polysorbates are stable to 
electrolytes and weak acids and bases; gradual saponification occurs with 
strong acids and bases Polysorbates are hygroscopic and should be 
examined for water content prior to use and dried if necessary. 
Polysorbates should be stored in a well-closed container, protected from 
light, in a cool, dry place. 
INCOMPATIBILITIES: Discoloration and/or precipitation occur with 
various substances, especially phenols, tannins, tars, and tar like 
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materials. The antimicrobial activity of paraben preservatives is reduced in 
the presence of polysorbates. 
SAFETY: The WHO has set an estimated acceptable daily intake for 
polysorbates 20, 40, 60, 65, and 80, calculated as total polysorbate esters, 
at up to 25 mg/kg body-weight. Polysorbate 80: moderately toxic by IV 
route. Mildly toxic by ingestion, Eye irritation, Experimental tumorigen, 
reproductive effects, Mutogenic data. 
• LD50 (mouse, IP): 7.6 g/kg,  LD50 (mouse, IV): 4.5 g/kg 
• LD50 (mouse, oral): 25 g/kg, LD50 (rat, IP): 6.8 g/kg 
HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Eye protection and 
gloves are recommended. 
 
LACTOSE MONOHYDRATE 
NONPROPRIETARY NAMES 
• BP : Lactose monohydrate 
• PhEur : Lactosum monohydricum 
• JP : Lactose 
• USPNF : Lactose monohydrate 
 
SYNONYMS: Aero Flo 20; Aero Flo 65; Aero Flo 95; Anhydrox; CapsuLac; 
Microfine; Microtose; Pharmatose; PrismaLac; Lactochem; Lactopress; 
Super – Tab; Zeparox.  
CHEMICAL NAME AND CAS REGISTRY NUMBER: O-β-D-
Galactopyranosyl-(1→4)-α-D-glucopyranose monohydrate [64044-51-5] 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: C12H22O11·H2O 
360.31 
Chapter 4  Excipient Profile 
 64
STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY: Binding Agent; Diluent for dry-powder 
Inhalers; Tablet Binder; Tablet and Capsule Diluent. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Lactose is 
widely used as a filler or diluent in tablets and capsules, and to a more 
limited extent in lyophilized products and infant formulas. Lactose is also 
used as a diluent in dry-powder inhalation. Usually, fine grades of lactose 
are used in the preparation of tablets by the wet-granulation method or 
when milling during processing is carried out, since the fine size permits 
better mixing with other formulation ingredients and utilizes the binder 
more efficiently. Other applications of lactose include use in lyophilized 
products, where lactose is added to freeze-dried solutions to increase plug 
size and aid cohesion. Lactose is also used in combination with sucrose 
(approximately 1: 3) to prepare sugar-coating solutions.  
DESCRIPTION: Lactose occurs as white to off-white crystalline particles 
or powder. Lactose is odorless and slightly sweet-tasting; α-lactose is 
approximately 20% as sweet as sucrose, while β-lactose is 40% as sweet. 
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TYPICAL PROPERTIES: 
Solubility: 
TABLE NO. 22: SOLUBILITY OF LACTOSE 
Solvent Solubility at 20°C unless otherwise stated
Chloroform Practically insoluble 
Ethanol Practically insoluble 
Ether Practically insoluble 
Water 1 in 5.24 
 1 in 3.05 at 40°C 
 1 in 2.30 at 50°C 
 1 in 1.71 at 60°C 
 1 in 0.96 at 80°C 
 
SAFETY: Adverse reactions to lactose are largely attributed to lactose 
intolerance, which occurs in individuals with a deficiency of the intestinal 
enzyme lactase. This results in lactose being undigested and may lead to 
cramps, diarrhea, distension, and flatulence. The symptoms of lactose 
intolerance are caused by the osmotic effect of the unabsorbed lactose, 
which increases water and sodium levels in the lumen. Unabsorbed 
lactose, upon reaching the colon, can be fermented by colonic flora, which 
produces gas, causing abdominal distension and discomfort. 
 In the past, there have been concerns over the transmissible 
spongiform encephalopathies (TSE) contamination of animal-derived 
products. However, in the light of current scientific knowledge, and 
irrespective of geographical origin, milk and milk derivatives are reported 
as unlikely to present any risk of TSE contamination; TSE risk is negligible 
if the calf rennet is produced in accordance with regulations. 
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LD50 (rat, IP): >10 g/kg 
LD50 (rat, oral): >10 g/kg 
LD50 (rat, SC): >5 g/kg 
HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Excessive generation 
of dust, or inhalation of dust, should be avoided. 
 
COLLOIDAL SILICON DIOXIDE 
NONPROPRIETARY NAMES 
• BP : Colloidal anhydrous silica 
• PhEur : Silica colloidalis anhydrica 
• USPNF : Colloidal silicon dioxide 
 
SYNONYMS: Aerosil; Colloidal Silica; Fumed Silica; light Anhydrous Silicic 
Acid; Silicic Anhydride; Silicon Dioxide fumed;  
CHEMICAL NAME AND CAS REGISTRY NUMBER: Silica [7631-86-9] 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: SiO2 60.08 
STRUCTURAL FORMULA: SiO2 
FUNCTIONAL CATEGORY: Adsorbent; Anticaking agent; Emulsion 
Stabilizer; Glidant; Suspending agent; Tablet Disintegrant; Thermal 
Stabilizer; Viscosity-Increasing Agent. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Colloidal 
silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products. Colloidal silicon dioxide is also used to stabilize emulsions and 
as a thixotropic thickening and suspending agent in gels and semisolid 
preparations. In aerosols, other than those for inhalation, colloidal silicon 
dioxide is used to promote particulate suspension, eliminate hard settling, 
and minimize the clogging of spray nozzles. Colloidal silicon dioxide is also 
used as a tablet disintegrant and as an adsorbent dispersing agent for 
liquids in powders. Colloidal silicon dioxide is frequently added to 
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suppository formulations containing lipophilic excipients to increase 
viscosity, prevent sedimentation during molding, and decrease the release 
rate. as a thickening agent for topical preparations; and has been used to 
aid the freeze-drying of nanocapsules and nanosphere suspensions. 
TABLE NO. 23: USES OF COLLOIDAL SILICON DIOXIDE 
Use Concentration (%) 
Aerosols 0.5–2.0 
Emulsion stabilizer 1.0–5.0 
Glidant 0.1–0.5 
Suspending and thickening agent 2.0–10.0 
 
DESCRIPTION: Colloidal silicon dioxide is submicroscopic fumed silica 
with a particle size of about 15 nm. It is a light, loose, bluish-white-colored, 
odorless, tasteless, nongritty amorphous powder. 
TYPICAL PROPERTIES: Solubility: Practically insoluble in organic 
solvents, water, and acids, except hydrofluoric acid; soluble in hot 
solutions of alkali hydroxide. Forms a colloidal dispersion with water. 
STABILITY AND STORAGE CONDITIONS: Colloidal silicon dioxide is 
hygroscopic but adsorbs large quantities of water without liquefying. 
Colloidal silicon dioxide powder should be stored in a well-closed 
container. 
INCOMPATIBILITIES: Incompatible with diethylstilbestrol preparations. 
SAFETY: Colloidal silicon dioxide is widely used in oral and topical 
pharmaceutical products and is generally regarded as an essentially 
nontoxic and nonirritant excipient. However, intraperitoneal and 
subcutaneous injection may produce local tissue reactions and/or 
granulomas. Colloidal silicon dioxide should therefore not be administered 
parenterally. 
LD50 (rat, IV): 15 mg/kg, LD50 (rat, oral): 3.16 g/kg 
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HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Eye protection and 
gloves are recommended. Precautions should be taken to avoid inhalation 
of colloidal silicon dioxide. For larger quantities, a dust respirator is 
recommended. 
 
MAGNESIUM STEARATE 
NONPROPRIETARY NAMES 
• BP : Magnesium stearate 
• JP : Magnesium stearate 
• PhEur : Magnesii stearas 
• USPNF   Magnesium stearate 
 
SYNONYMS: Magnesium Octadecanoate; Octadecanoic Acid, 
Magnesium Salt; Stearic Acid, Magnesium salt. 
CHEMICAL NAME AND CAS REGISTRY NUMBER: Octadecanoic acid 
magnesium salt [557-04-0]. 
EMPIRICAL FORMULA AND MOLECULAR WEIGHT: C36H70MgO4 
591.34. 
STRUCTURAL FORMULA: [CH3 (CH2)16COO]2 Mg. 
FUNCTIONAL CATEGORY: Tablet and Capsule Lubricant. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION: Magnesium 
stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet 
manufacture at concentrations between 0.25% and 5.0% w/w. It is also 
used in barrier creams. 
DESCRIPTION: Magnesium stearate is a very fine, light white, 
precipitated or milled, impalpable powder of low bulk density, having a 
faint odor of stearic acid and a characteristic taste. The powder is greasy 
to the touch and readily adheres to the skin. 
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TYPICAL PROPERTIES: Solubility: Practically insoluble in ethanol, 
ethanol (95%), ether and water; slightly soluble in warm benzene and 
warm ethanol (95%). 
STABILITY AND STORAGE CONDITIONS: Magnesium stearate is stable 
and should be stored in a well-closed container in a cool, dry place. 
INCOMPATIBILITIES: Incompatible with strong acids, alkalis, and iron 
salts. Avoid mixing with strong oxidizing materials. Magnesium stearate 
cannot be used in products containing aspirin, some vitamins, and most 
alkaloidal salts. 
SAFETY: Magnesium stearate is widely used as a pharmaceutical 
excipient and is generally regarded as being nontoxic following oral 
administration. However, oral consumption of large quantities may 
produce a laxative effect or mucosal irritation. No toxicity information is 
available relating to normal routes of occupational exposure. Toxicity 
assessments of magnesium stearate in rats have indicated that it is not 
irritating to the skin, and is nontoxic when administered orally or inhaled. 
Magnesium stearate has not been shown to be carcinogenic when 
implanted into the bladder of mice. 
LD50 (rat, inhalation) : >2 mg/L 
LD50 (rat, oral) : >10 g/kg 
HANDLING PRECAUTIONS: Observe normal precautions appropriate to 
the circumstances and quantity of material handled. Eye protection and 
gloves are recommended. Excessive inhalation of magnesium stearate 
dust may cause upper respiratory tract discomfort, coughing, and choking. 
Magnesium stearate should be handled in a well-ventilated environment; a 
respirator is recommended. 
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LITERATURE REVIEW 
 
 Van Kam et al., (1983)22 studied the crushing strength, 
disintegration and dissolution properties of tablets, made by wet 
granulation with lactose as filter, gelatin as binder, potato starch as 
disintegrant and magnesium stearate as lubricant can be markedly 
improved when the potato starch (20%) is replaced by a much lower 
concentration (4%) of an insoluble superdisintegrant, such as sodium 
starch glycolate (Primogel) or crospovidone (Polyplasdone XL). The 
incorporation of partially water soluble superdisintegrants such as low-
substituted sodium carboxymethylcellulose (Nymcel, ZSD 16), causing a 
viscous barrier in the tablet disintegration and drug release. In contract to 
potato starch, the position of the superdisintegrants (intragranular, 
extragranular or equally distributed) had hardly any effect on the tablet 
properties. The improved properties of the tablets containing insoluble 
superdisintegrants, when compared to tablets with potato starch, are the 
result of the use of much lower concentration of disintegrant, but especially 
of the difference in effect of magnesium stearate on the disintegration 
capacity of the slightly swelling potato starch and the strongly swelling 
superdisintegrants, respectively. The latter cause, even in the presence of 
the liquid penetration inhibiting hydrophobic magnesium stearate, a chain 
reaction of opening of the tablet, starting at the outside and resulting in a 
fast disintegration. 
 Salom I L et al., (1984)23 Etodolac, a nonsteroidal anti-
inflammatory and analgesic drug, was used in a randomized, parallel 
group, open-label design study, with stool analysis conducted in a blind 
fashion, to compare its effect in normal men in doses of 400 mg (N = 11) 
and 600 mg (N = 12) b.i.d. [twice daily] on gastrointestinal microbleeding 
with that of 600 mg ibuprofen, q.i.d. [4 times a day] (N = 12), 50 mg 
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Indomethacin in the morning, 50 mg at noon, 100 mg h.s. {N = 9} and 375 
mg naproxen b.i.d. (N = 9). Etodolac was given about 2.5 and 3.5 times 
the mean effective dose used for treating patients with rheumatoid arthritis. 
The other drugs were given at their manufacturer’s maximum 
recommended doses. Lead-in placebo was given for 1 week, active drug 
for 1 week and wash out placebo for 1 week. Fetal blood loss was 
measured by the 51 Cr tragged red cell method, and was averaged over 
days 4-7 (base line), 11-14 (treatments period) and 17-20 (wash out). The 
mean increase in blood loss for the treatment period for the 400 mg 
Etodolac b.i.d. group (0.13 ml) and 600 mg Etodolac b.i.d. (0.10 ml) was 
significantly less (p = 0.001) than the corresponding valves for Ibuprofen 
(1.14 ml), Indomethacin (1.20 ml) and Naproxen (0.87 ml). There was no 
tendency for greater blood loss at higher doses of Etodolac. Etodolac at 
doses in excess of the mean effective dose in osteoarthritis and 
rheumatoid arthritis caused significantly less microbleeding in normal male 
volunteers during the 7-day treatment period than the other drugs, tested 
and not clinically more than that occurring during baseline placebo. 
 Gaston G W et al., (1986)24 single oral doses of Etodolac 50, 100 
and 200 mg were compared with Aspirin 650 mg in a placebo in a double-
blind, parallel group study of 189 out patients reporting moderate or sever 
pain after oral surgery. Over all efficacies of test drugs was evaluated by 
sum of pain intensity difference (SPID) source and total pain relief 
(TOTPAR) scores over 0.5-3, 0.5-6, 0.5-8 and 0.5-12 hours. Etodolac  
200 mg provided significantly greater analgesia than Aspirin by these 
measurements over all SPID and all but one TOPAR interval, and was 
significantly more effective than placebo over all intervals. Etodolac  
100 mg was superior to Aspirin for SPID 0.5-8 and 0.5-12 hours and 
superior to placebo for both SPID and TOTPAR over all time intervals. 
Onset of analgesia for Etodolac 100 mg, 200 mg and Aspirin was 1 hour or 
less for the majority of patients in each group; 42% receiving Etodolac 200 
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mg reported onset of analgesia within 0.5 hour. Duration of analgesia for 
Etodolac 200 mg appeared twice that of Aspirin. A significant positive 
dose-response relationship was obtained for the three doses of Etodolac. 
A low frequent of side effects was observed in all treatments groups. 
 Gordon et al., (1987)25 studied the effect of tablet composite 
solubility and hygroscopicity on the dissolution efficiency of three 
“superdisintegrants”, sodium starch glycolate, crospovidone and 
croscarmelose sodium, was investigated. Lactose, dicalcium phosphate 
dehydrate, and sorbitol, alone or in combination, provided varying degrees 
of solubility and hygroscopicity to the direct compression tablet 
formulations. To monitor in vitro dissolution. 1% p-amino benzoic acid was 
added to the formulation as a tracer. The results indicate that hygroscopic 
ingredients decrease the effectiveness of superdisintegrants in promoting 
in vitro dissolution. The greater the overall hygroscopicity of the tablet 
formulation, the larger the decrease in the efficiency of the 
superdisintegrant. Composite tablet solubility did not influence the 
effectiveness of the superdisintegrants. Superdisintegrants that compiled 
with the same compendia specification, but were manufactured by 
different companies, behaved similarly in promoting tablet dissolution. 
 Kraml M et al., (1988)26 the pharmacokinetics of Etodolac have 
been evaluated in five patients with arthritis given 200 mg Etodolac, twice 
daily, at 12 hour intervals, for 7 days. Albumin and total protein 
concentrations were markedly lower in synovial fluid than in serum, and 
Etodolac free fraction was significantly higher. Etodolac readily penetrated 
into the synovial fluid, and in the post distributive phase the concentration 
of free Etodolac (i.e., the drug responsible for pharmacologic activity) 
remained higher than that in serum at all times. No differences in the half-
life of Etodolac elimination were noted. 
 Sangali et al., (1989)27 studied that the dissolution rate is often the 
limiting step in gastrointestinal absorption of water insoluble drugs from 
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solid oral dosage forms. The aim of this work was to use a swellable 
polymer chosen among superdisintegrants, for improving the dissolution 
rate of a sparingly soluble drug, loaded on its surface. Nifedipine, which 
has very low water solubility, was chosen as a model drug, while cross 
linked sodium carboxymethyl cellulose (Ac-Di-Sol) was chosen as the 
swellable polymer. The Nifedipine /Ac-Di-Sol systems were prepared using 
two different techniques: evaporation and spraying; in some preparations 
polyethylene glycol (PEG 1500), sucrose palmitate (Sucrodent), or dioctyl 
sodium sulfosuccinate (Aerosal OT) were added. The results of the 
dissolution tests showed that the dissolution rate of Nifedipine from the 
systems prepared increase, particularly in the case of the preparation 
composed of Ac-Di-Sol plus surfactant agents. 
 Zvaifler N (1989)28 Etodolac (Lodine, Ramodar, Ultradol), an anti-
inflammatory, analgesic agent, is the first of a new class of nonsteroidal 
anti-inflammatory drugs (NSAIDs), the pyranocarboxylic acids. A review of 
the literature on numerous clinical studies showed that Etodolac (200 to 
600 mg/day) is effective in the treatment of osteoarthritis and rheumatoid 
arthritis. Etodolac has also been shown to be very well tolerated. In 
double-blind studies, there were no significant differences in the 
incidences of new patient complaints except for indigestion between 
Etodolac-treated groups and placebo-treated groups. Gastrointestinal 
microbleeding associated with Etodolac was comparable to that with 
placebo and was significantly less than that associated with other 
commonly used NSAIDs, such as Ibuprofen, Indomethacin, Piroxicam, and 
naproxen. The results of laboratory tests, including a detailed analysis of 
hepatic and renal function, have revealed few abnormalities, most of which 
were clinically unimportant. When administered to healthy subjects, 
Etodolac had no pharmacokinetic interactions with three other drugs that 
are highly bound to serum protein: warfarin, glyburide, and phenytoin. 
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 Brater D C (1990)29 nonsteroidal anti-inflammatory drugs have 
been implicated in renal impairment. The purpose of this report is to review 
the effect of Etodolac, a new anti-inflammatory agent, on renal function 
and the effect of renal impairment on Etodolac pharmacokinetics. 
Pharmacokinetics and renal function studies were conducted in normal 
and in renally impaired volunteers. Additionally, the renal safety of 
Etodolac was assessed in 2,629 arthritic patients who were treated in 
clinical trails. The results suggest that Etodolac does not affect renal 
function in normal individuals, nor does it exacerbate underlying renal 
insufficient when administered to patients with mild to moderate renal 
impairment. The pharmacokinetics of Etodolac is unchanged in patients on 
hemodialysis and in elderly patients. Furthermore, no patient was 
withdrawn from clinical trails for significantly abnormal renal function test 
values resulting from Etodolac therapy alone. 
 Gordon et al., (1990)30 performed a computer-optimized 
experimental design used to study the effect of incorporating a 
“superdisintegrant”, croscarmelose sodium, intragranularly, 
extragranularly, or distributed equally between the two phases of a tablet 
in which a poorly soluble drug constituted at least 92.5% of the 
formulation. The results were analysed by means of a general quadratic 
response surface model and suggest that tablets with the same total 
concentration of superdisintegrant is included intragranularly. Tablet 
friability was not affected by the method of superdisintegrant incorporation. 
 Johnson et al., (1991)31 studied the effect of tablet formulation 
solubility and hygroscopicity on the dissolution efficiency of three 
“superdisintegrants (sodium starch glycolate, crospovidone, and 
croscarmelose sodium) in tablets prepared by wet granulation was 
investigated. Lactose, calcium phosphate dibasic, sorbitol and naproxen 
sodium, alone or in combination, provided varying degrees of solubility and 
hygroscopicity in the formulations. To monitor in vitro dissolution, 1% of 
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para-aminobenzoic acid was added to the formulation as a tracer. The 
results indicate that highly soluble and/or hygroscopic ingredients 
decrease the effectiveness of superdisintegrants in promoting in vitro 
dissolution. The greater the overall hygroscopicity and solubility of the 
tablet formulation the larger is the decrease in the efficiency of the 
superdisintegrant. 
 Rudraraju et al., (1993)32 investigated the effect of mode of 
superdisintegrant incorporation in wet granulated tablets with three 
superdisintegrants: sodium starch glycolate, crospovidone, and 
croscamelose sodium. This disintegrants were incorporated 
extragranularly or intragranularly or distributed equally between the two 
phases. Lactose, naproxen, or dibasic calcium phosphate was used as the 
principal tablet component to provide various degrees of solubility to the 
formulations. The formulations were dried to three different levels of 
moisture content. The results indicated that, for the formulations studied, 
extragranular incorporation resulted in faster dissolution than did equal 
distribution intragranularly and extragranularly, which in turn was superior 
to intragranular incorporation. Granulation moisture content was found to 
have a formulation-specific impact on tablet dissolution, with each main 
tablet component behaving in a different fashion. When all other factors 
were kept constant, there was a tendency for croscarmelose sodium to 
produce faster tablet dissolution than sodium starch glycolate or 
crospovidone. The superdisintegrants tended to promote faster dissolution 
in a neutral pH medium than in an acidic medium 
 Ahamed et al., (1994)33 studied the influence of various 
temperature and relative humidity conditions on changes in hardness and 
friability of five commercial brands of packaged paracetamol tablets stored 
over a period of six months has been investigated. At 75% of RH all 
sample show deterioration in harness at 25 degrees (5-10%) and at 45 
degrees (10-39%). AT 100% RH there is a -1 little difference in 
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deterioration in hardness at 25 degree (16-24%) and 45 degree (20-28%) 
suggesting that once the critical moisture content is reached by the tablets, 
further increase in relative humidity has little effect on changes in 
hardness. Under the same conditions, all tablets show an increase in 
friability ranging from 2.83 to 8.02%. The overall increase in friability with 
an increase in temperature from 25 degrees to 45 degrees at 75% and 
100% RE is 0.0 to 25.2%. The results indicate that moisture sorption by 
tablet matrix through certain packaging materials may adversely affect the 
hardness and friability characteristics. 
 Kichiro Inoue et al., (1994)34 the anti-inflammatory effect of 
Etodolac (Eto) were compared with those of 6 other anti-inflammatory 
drugs: Indomethacin (Ind), Diclofenac Na (Dic), Piroxicam (Pir), Naproxen 
(Nap), Ketoprofen (Ket), and Aspirin (Asp). Eto inhibited carrageenin-
induced edema in rats, adjuvant-induced arthritis in rats, acetic acid-
induced writhing in mice and brewer’s yeast-induced hyperalgesia and 
fever in rats. In the adjuvant arthritis test, the ED30 value (1.88 mg/kg) on 
day 3 and ED50 values (adjuvant-injected paw: 1.18 mg/kg and non-
injected paw: 0.96 mg/kg) on day 18 for Eto were comparable to those for 
Dic (2.16, 1.72 and 1.28) when given prophylactically and the ED50 values 
for Eto (adjuvant-injected paw: 1.61 and non-injected paw: 1.20 mg/kg) 
were comparable to those for Ket (1.24 and 1.22) when used 
therapeutically. The analgesic activity of Eto (ED50 value: 3.67 mg/kg) in 
the acetic acid –induced writhing test was greater than that of Nap (9.83) 
or Asp (31.6) and less than that of Ind (0.71), Dic (1.54), Pir (0.92) or Ket 
(1.34). In the antipyretic test, the minimum effective dose (MED: 1 mg/kg) 
for Eto was comparable to that for Ind (1.0), Nap (1.0), Ket (1.0). Eto was 
less potent in inhibiting carrageenin-induced edema (ED30 value: 6.99 
mg/kg) and inflammatory pain (ED50 value: 9.24mg/kg) than the other 
drugs (Ind: 2.32 & 3.47, Dic: 0.69 & 3.80, Pir: 1.31 & 1.94, Nap: 1.83 & 
2.78, Ket: 1.12 & 0.63), except for Asp (167 & 51.8). Eto was the least 
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ulcerogenic (UD50 value: the dose which cause ulcer action in 50% rats: 
84.2 mg/kg) compound among the drugs tested (Ind: 4.24, Dic: 12.7, Pir: 
3.14, Nap: 42.3, Ket: 2.69, Asp: 20.8), so its safety margin (the ratio of the 
UD50 value to the ED30, ED50 or MED value) was greater than those of the 
other drug. Thus, Eto is considered to be an effective anti-inflammatory 
drug with weak ulcerogenic activity. 
 LJ et al., (1996)35 study the influence of intra and extragranular 
microcrystalline cellulose (MCC) on drug dissolution from tablets made by 
high-shear granulation. Granulations were made in a Littleford Model W-
10-B (10-liter) mixer and dried in a fluid bed dryer (Niro Inc.) A Plackett 
Burman Screening design and 2(3) factorial design were employed to 
study how drug type, MCC (intra-, or extra-), filler type (lactose or 
dicalcium phosphate), disintegrant type (sodium starch glycolate or 
croscarmelose sodium) and level, proportion of magnesium stearate, and 
impeller speed affect tablet hardness, disintegration time, and dissolution. 
Two model drugs were chosen based on their solubility: metoprolol tartrate 
(solubility >1000 mg/ml) and hydrochlorothiazide (solubility = 1.05 mg/ml). 
Tablets were compressed to the same target weight (dose) and similar 
tablet hardness. In some cases, dissolution testing was also carried out on 
the loose granules. The intra extragranular distribution of MCC was found 
critical to the compactability and initial dissolution rates from these tablets. 
Intragranular MCC reduced drug dissolution, the effect being most marked 
in the case of the slightly soluble hydrochlorothiazide. For formulations 
containing intragranular MCC, the granulating fluid level on tablet 
dissolution was also important, since an increase in fluid level resulted in 
slower drug dissolution from both the loose granules and the tablets 
compressed from them. Conversely, extragranular MCC tended to 
increase both dissolution rates and compactability. It may be concluded 
that the appropriate distribution of MCC between and within granules may 
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optimize both dissolution and compactability without changing overall 
tablet composition. 
 Rekhi et al., (1997)36 reported the impact of formulation and 
process changes on dissolution and bioavailability / bioequivalence of 
metoprolol tartrate immediate release tablets manufactured using a high-
shear granulation process. Changes in sodium starch glycolate and 
magnesium stearate level, and the order of addition microcrystalline 
cellulose (intra vs. extragranular) were significant only in affecting percent 
drug release (Q) in 5, 10, and 15 minutes. Statistical analysis of data 
showed no significant curvature. No examine the impact of formulation and 
processing variables on in vivo absorption, three batches were selected for 
a bioavailability study based on their dissolution profiles. Subjects received 
four metoprolol treatments (Lopressor, slow, medium and fast dissolving 
formulations) separated by I week according to a randomized crossover 
design. After an overnight fast, subjects were administered one tablet (100 
mg), blood samples were collected over 24 hrs and plasma samples were 
analyzed. The formulations were found to be bioequivalent with respect to 
the log Cmax and log0-α. The results of this study suggest that (i) 
bioavailability/ bioequivalence studies may not be necessary for metoprolol 
tartrate immediate release tablet and perhaps other class I drugs after 
level 2 type changes and (II) in vitro dissolution tests may be used to slow 
bioequivalence of metoprolol formulations with processing or formulation 
changes within the specified level 2 ranges for the equipment examined. 
 Chen et al., (1998)37 studied the disintegration and dissolution of 
acetaminophen tablets containing sucrose and Ac-Di-Sol/Primogel was 
significantly different between acidic and neutral media. The purpose of 
this study was to investigate the mechanism of this phenomenon and to 
propose a way of reducing the dissolution difference between the two 
media. Tablets of different combinations of active ingredient, sucrose, and 
Ac-Di-Sol/Primogel were prepared and their dissolution in various media 
Chapter 5  Literature Review 
 79
was evaluated. The dissolution differences were found to be largely 
related to the hydrophobicity of the active ingredient and pH difference of 
the two media. This difference was even more evident under the condition 
where acetaminophen, sucrose, and Primogel were combined. The 
dissolution difference was therefore attributed to the depressed function of 
Primogel in the acidic medium, the stronger binding of sucrose, the 
hydrophobicity of the active ingredient and pH difference of the two media. 
Increasing the concentration of Primogel or incorporating the surfactant in 
the tablet can thus greatly decrease the dissolution difference between 
acidic and neural media. 
 Richard A. Jones (1999)38 Etodolac nonsteroidal anti–
inflammatory drug (NSAIDs), which has been shown to be effective in the 
treatment of rheumatoid arthritis and osteoarthritis and a selective COX-2 
inhibitor in a wide range of clinically relevant assays in direct comparisons 
with other NSAIDs. Studies have shown Etodolac to have no overall 
suppression of gastric or duodenal prostaglandins and endoscopic 
analysis with Etodolac showed placebo level score in comparison with 
Ibuprofen, which showed inducement of gastro-intestinal (GI) side effects. 
This high degree of gastric tolerability was further demonstrated by 
microbleeding studies. The favorable GI tolerability profile of Etodolac has 
been shown in long-term and large-scale trails and by routine clinical 
observation. In summary, Etodolac is a well established selective COX-2 
inhibitor that has been shown not to suppress gastric or duodenal 
prostaglandins, to have minimal hepatic or renal effects and to have 
favorable GI tolerability in comparison with Ibuprofen 
 Lopex-Solis et al., (2001)39 studied the effect of disintegrant 
hygroscopicity on dissolution of tablets obtained by compression at 85 
MPa of mixtures of Norfloxacin and different proportions of a disintegrant 
(starch 1500, PVP XL 10 or Croscarmelose sodium) and a diluents 
(Pharmatose DCL 11). Dissolution behavior was evaluated according to 
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USP23, apparatus 2 (paddle) at 50 rpm and using 750 ml acetate buffer 
solution of pH 4, at 37 degrees C, as medium. Norfloxacin added of 
increasing proportions, in a given range, of each disintegrant or the 
diluents increased the drug dissolved. Addition of increasing proportions of 
pharmatose DCL 11 to Norfloxacin with 5% of the high hygroscopic starch 
1500 reduced the dissolution improvement effect of pharmatose DCL 11. 
Addition of 5% pharmatose DCL 11 to tablets of the middle hygroscopic 
Croscarmelose sodium and Norfloxacin slightly reduced the 
croscarmelose sodium dissolution promoting effect, while addition of 15% 
pharmatose DCL 11 to tablets of the low hygroscopic PVP XL 10 and 
Norfloxacin showed no inhibition but potentiated substantially the 
dissolution of Norfloxacin. These effects were attributed to competition for 
the available water in the tablet and to different water consume, for 
dissolution or hydration, by the diluents and the disintegrants. 
 L.H.Reddy et al., (2002)40 recently, fast-dissolving drug delivery 
systems have started gaining popularity and acceptance as a new drug 
delivery systems, because they are easy to administer and lead to better 
patient compliance. Usually, elderly people experience difficulty in 
swallowing the conventional dosage forms because of tremors of 
extremities and dysphagia. Fast-dissolving drug delivery systems may 
offer a solution for these problems. Fast-dissolving drug delivery systems 
can be achieved by various techniques like direct compression, wet 
granulation, compression moulding, volatization and freeze-drying. They 
involve different mechanisms like use of high amounts of hydrophilic 
disintegrating agents of effervescent combinations, which allow the 
dosage forms to disintegrate quickly in the patient’s mouth on constant 
with saliva. There are more than fifteen fast-dissolving products in the 
market worldwide. 
 Shenoy et al., (2003)41 prepared the fast dissolving tablets of 
diclofenac sodium using direct compression after incorporating 
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superdisintegrants such as cross linked carboxymethylcellulose, sodium 
starch glycolate and cross linked povidone in different concentrations. All 
the formulations were evaluated for the influence of disintegrants and their 
concentrations on the characteristics of fast dissolving tablet mainly in 
terms of disintegration time and dissolution rate. Tablets containing cross-
linked carboxymethylcellulose showed better disintegrating character 
along with rapid release (90 percent drug release in 10 min). No 
appreciable difference was found between the formulations containing 
other two superdisintegrants. The concentration of the superdisintegrants 
had also an effect on disintegration time and in vitro dissolution. There 
seems to be a trend towards use of higher level of disintegrants producing 
rapid disintegration and faster dissolution. The resulting tablets were also 
evaluated for its hardness and friability and were found to be independent 
of disintegrant concentration. 
 Nayak S. M et al., (2004)42 the present study is about a tablet, 
which can disintegrate or dissolve rapidly once placed into the oral cavity. 
Fast dissolving tablets of promethazine thecolate were prepared using 
effervescent melt, superdisintegrant addition and melt technologies. All the 
prepared formulations were evaluated for various granule and tablet 
characteristics. Significant rapid release of drug from the formulated 
tablets was observed in comparison to the control tablets. Tablets from 
effervescent melt and superdisintegrant addition technique release 92% 
and 89% of the drug at the end of 10 minutes respectively. Study 
concluded fast dissolving tablets of promethazine theoclate could be 
prepared successfully. Tablets with added patient benefits and increased 
consumer satisfaction. 
 Stephen L. et al., (2005)43 the increasing use of nonsteroidal anti-
inflammatory drugs (NSAIDs) in small animals has resulted in the 
development of new and innovative additions to this class of drugs. 
Examples of NSAIDs now available for use in small animals include 
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aspirin, Etodolac, Carprofen, Ketoprofen, Meloxicam, Deracoxib, and 
Tepoxalin. The purposes of this article are to review the pathophysiology 
of prostaglandin synthesis and inhibition, the mechanisms of action, 
pharmacokinetics, pharmacological effects, and potential adverse 
reactions of aspirin and the newly released NSAIDs. 
 Souliman S et al., (2006)44 the first purpose of this study was to 
simulate the impact of food intake on drug release and absorption in vivo 
using a novel in vitro system which mimics the gastro-intestinal (GI) tract in 
man. The drug studied was acetaminophen in the form of immediate 
release (IR) tablets. The second purpose was to establish a level an  
in vitro / in vivo correlation that could predict the bioavailability of a drug 
instead of using difficult, time-consuming and expensive in vivo 
bioequivalence studies. The artificial digestive system was used to 
estimate the availability of acetaminophen IR tablets for absorption in 
fasted and fed states. The same study was performed in vivo under similar 
conditions. A comparison study was carried out between the classical and 
the novel methods to estimate the efficacy of the new in vitro system to 
simulate the influence of food on drug release and absorption in vivo. A 
level A in vitro / in vivo correlation was established with a correlation 
coefficient of 0.9128 and 0.9984 in the fasted and fed states, respectively. 
Compared to USP II method, the novel in vitro model demonstrated a high 
level of efficacy in mimicking the behavior of acetaminophen IR tablets in 
vivo in fasted and fed states. 
 Manzo RH et al., (2006)45 Literature data relevant to the decision to 
allow a waiver of in vivo bioequivalence (BE) testing for the approval of 
immediate release (IR) solid oral dosage forms containing Amitriptyline 
hydrochloride are reviewed. Its therapeutic uses, its pharmacokinetic 
properties, the possibility of excipient interactions and reported 
BE/bioavailability (BA) problems are also taken into consideration. 
Literature data indicates that amitriptyline hydrochloride is a highly 
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permeable active pharmaceutical ingredient (API). Data on the solubility 
according to the current Biopharmaceutics Classification System (BCS) 
were not fully available and consequently amitriptyline hydrochloride could 
not be definitively assigned to either BCS Class I or BCS Class II. But all 
evidence taken together, a biowaiver can currently be recommended 
provided that IR tablets are formulated with excipients used in existing 
approved products and that the dissolution meets the criteria defined in the 
Guidances. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists 
Association 
 Dukić-Ott A, et al., (2007)46 the aim of this study was to evaluate 
modified starch (high-amylose, crystalline and resistant starch) as the 
main excipient for immediate-release pellets containing poorly soluble 
drugs (hydrochlorothiazide and piroxicam) and prepared via extrusion / 
spheronisation. The bioavailability of pellets (containing 50 mg 
hydrochlorothiazide) was determined after oral administration to 6 dogs. A 
2(4)-factorial design with central point was used to evaluate the influence 
of hydrochlorothiazide (10% and 50%, w/w), HPMC (binder, 4% and 7%, 
w/w), sorbitol (0% and 10%, w/w) and water (granulation liquid, low and 
high level) on pellet yield, size (Feret mean diameter) and sphericity 
(aspect ratio and two-dimensional shape factor). Optimal granulation liquid 
content depended on drug and sorbitol level in the formulation. All factors 
except sorbitol content, as well as the interactions between drug 
concentration and binder level and between drug and water level, were 
significant (P<0.05) for pellet yield, while a significant curvature (P<0.05) 
suggested non-linearity of the response plots. The model was not 
significant for pellet shape, while hydrochlorothiazide and water level as 
well as their interaction were significant (P<0.05) for pellet size. Pellet 
friability, disintegration, residual water content and in-vitro drug release 
were determined. Pellets containing 2.5% (w/w) piroxicam were also 
evaluated. For both model drugs, pellets with a high yield (>90%), 
Chapter 5  Literature Review 
 84
acceptable sphericity (AR<1.2) and low friability (<0.01%) were obtained. 
Due to pellet disintegration, fast dissolution of both hydrochlorothiazide 
and piroxicam was achieved: >80% drug released in 30 min. The 
bioavailability (AUC0>24 h, Cmax and tmax) of hydrochlorothiazide pellets in 
dogs was not significantly different from fast-disintegrating immediate-
release hydrochlorothiazide tablets (P>0.05). 
 El-Barghouthi M, et al., (2008)47 Disintegrants and fillers represent 
important excipients for immediate-release solid dosage forms in many 
pharmaceutical applications. A new excipient based on the coprecipitation 
of chitosan and silica has been achieved. The "intimate" physical 
association between chitosan and silica creates an insoluble, hydrophilic, 
highly absorbent material, consequently, resulting in superiority in water 
uptake, water saturation for gelling formation, and compactability among 
other superdisintegrants. The new excipient has an outstanding 
functionality that does not primarily depend on water wicking and swelling 
properties. In fact, it translates it into superior disintegration characteristics 
with improved powder flow and compaction properties. Thus, the new 
excipient could act as a superdisintegrant and pharmaceutical filler at the 
same time. Studies have shown that chitosan-silica delivers superior 
performance in wet granulation formulations and is the only disintegrant 
that is effective at all concentrations in tablet formulation. 
 Sekar V, Chellan VR (2008)48 Telmisartan (anti-hypertensive) is 
insoluble in water; hence the drug may be slowly or incompletely dissolved 
in the gastro intestinal tract. So the rate of dissolution and therefore its 
bioavailability is less (bioavailability 42%). In the present study an attempt 
has been made to prepare immediate release tablets of telmisartan by 
using Polyplasdone XL-10 (crospovidone) at intragranular, extragranular 
and partly intra and extragranular level of addition to increase the rate of 
drug release from dosage form to increase the dissolution rate and hence 
its bioavailability. The prepared granules and tablets were evaluated for 
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their physiochemical properties and in-vitro dissolution study was 
conducted for the prepared tablets. It was concluded that the immediate 
release tablets with proper hardness, disintegration time and with increase 
rate of dissolution can be made using Polyplasdone XL-10. Formulation-10 
(F10) was selected for stability study and the in-vitro dissolution study 
showed that was no difference in percent of drug released between initial 
and sixth month sample. 
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TABLE NO. 24: EQUIPMENTS USED FOR TABLET FORMULATION 
Name of equipment Name of company 
Tablet punching machine  Rimek Mini Press 1 
Tablet disintegration test apparatus  Remi equipments  
Pfizer tablet hardness tester  Scientific Engineering Corporation  
Roche friability tester  Remi equipments 
Dissolution apparatus Lab India Disso 2000 
UV spectrophotometer Jasco V 530 
FT IR  spectrophotometer (Jasco-FT-IR 8201 PC) 
pH tester 1 (water proof) Oakton instruments. 
Electronic Balance Alpha Innotech Corporation 
 
 
TABLE NO. 25: MATERIALS USED FOR TABLET FORMULATION 
Name of the materials Name of company 
Etodolac Dr. Reddy’s Laboratories, Hyderabad. 
Lactose SD Fine chemicals Ltd, Mumbai. 
Micro crystalline cellulose SD Fine chemicals Ltd, Mumbai. 
Crospovidone Aurobindo Pharmaceutical, Hyderabad. 
Sodium Starch Glycolate Aurobindo Pharmaceutical, Hyderabad. 
Magnesium stearate SD Fine chemicals Ltd, Mumbai. 
Povidone SD Fine chemicals Ltd, Mumbai. 
Colloidal Silicon dioxide SD Fine chemicals Ltd, Mumbai. 
Polysorbate 80 SD Fine chemicals Ltd, Mumbai. 
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ANALYTICAL METHODS 
 
METHODS AVAILABLE FOR THE IDENTIFICATION OF ETODOLAC 
ARE48 
a) Examine by infrared absorption spectrophotometry, comparing with 
the spectrum obtained with the spectrum obtained with Etodolac 
b) Melting point: 144°C to 150°C. 
c) The retention time of the major peak in the chromatogram of the 
Assay preparation corresponds to that in the chromatogram of the 
Standard preparation, as obtained in the Assay. 
 
METHODS AVAILABLE FOR ESTIMATION OF ETODOLAC ARE 
a) Spectrophotometric estimation of Etodolac in pure form and 
pharmaceutical formulation was reported.49 
b) Spectrofluorimetric determination of Etodolac was reported. The 
detection limit was reported to be 96 to 640 ng/ml.50 
c) The separation of Etodolac and its metabolites has been reported 
by the use of Capillary electro – chromatography.2 
d) HPLC and Mass spectrometry was reported for the determination of 
Etodolac in human plasma.51 
 
METHOD FOR ESTIMATION OF ETODOLAC 
A spectrophotometric method based on the measurement of 
absorbance at 274 nm in 0.1 M phosphate buffer pH 6.8 was used in the 
present study for estimation of Etodolac. 
 
MATERIALS 
1. Etodolac pure drug. 
2. Methanol. 
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3. Potassium dihydrogen phosphate. 
4. Sodium hydroxide 
5. Distilled water. 
 
THE METHODOLOGY USED IN THE PRESENT RESEARCH WORK52 
Preparation of pH 6.8 phosphate buffer: 
 250 ml of 0.2M potassium dihydrogen phosphate in a 100 ml vessel 
and 112 ml of 0.2 M NaOH and made up to 1000 ml with water. 
 
Potassium dihydrogen phosphate (0.2M) 
 Dissolve 27.218 g of potassium dihydrogen phosphate in water and 
dilute to 1000 ml with water. 
 
Sodium hydroxide (0.2M) NaOH 
 Dissolve 8 g of NaoH in water and dilute to 1000 ml with water. 
 
Preparation of standard stock solution 
 100 mg of Etodolac pure drug was dissolved in 2-4 ml of methanol 
in a 100 ml of volumetric flask and the solution was made up to the mark 
with phosphate buffer pH 6.8. 
 
Procedure for standard graph 
 The standard solution of Etodolac was subsequently diluted with  
0.1 M, pH 6.8 phosphate buffer to obtain a series of dilutions containing  
4 µg/ml, 8, 12, 16, 20, 24, 28 µg/ml of Etodolac in 1 ml solution. The 
absorbance of these solutions was measured in Shimadzu UV-1600  
UV- visible spectrophotometer using 0.1M, pH 6.8 phosphate buffer as 
blank. The concentration of Etodolac used and the corresponding 
absorbances were given in table no. 26 and the absorbance was plotted 
against different concentrations of Etodolac as shown in Figure No. 7. 
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TABLE NO. 26: STANDARD GRAPH VALUES OF ETODOLAC IN 0.1M, 
PH 6.8 PHOSPHATE BUFFER 
Concentration µg/ml Absorbance at 274 nm 
4 0.1187 
8 0.2350 
12 0.3550 
16 0.4701 
20 0.5906 
24 0.7050 
28 0.8295 
 
FIGURE NO. 7: STANDARD GRAPH OF ETODOLAC IN 0.1M, pH 6.8 
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FORMULATION OF ETODOLAC IMMEDIATE 
RELEASE TABLETS 
 
 Etodolac, is a Non Steroidal Anti-Inflammatory Drug (NSAID), of the 
pyranocarboxylic acid class. Etodolac is a synthesized anti-inflammatory 
drug with potent inhibitory activity against interleukin-1 beta (IL-1beta)-
induced prostaglandin E2 biosynthesis in chondrocytes. Etodolac, is water 
insoluble drug and soluble in methanol, chloroform, dimethyl sulfoxide, and 
aqueous polyethylene glycol. The ten different batches of Etodolac 
immediate release tablets were formulated by wet granulation method 
using two different superdisintegrants such as crospovidone (polyplasdone 
XL-10) and sodium starch glycolate in three different ratios (2%, 4%, 6%) 
by intra, extra and partly intra and extragranular addition method. 
INGREDIENTS 
TABLE NO. 27: INGREDIENTS FOR ETODOLAC IMMEDIATE 
RELEASE TABLETS 
Drug Etodolac, a nonsteroidal anti-inflammatory. 
Diluent Lactose monohydrate used as fillers (LMH). 
Disintegrant Microcrystalline cellulose (MCC). 
Superdisintegrants Crospovidone and Sodium Starch Glycolate help to 
dispersing the drug particle and used to increase the 
rate of drug release. 
Wetting agent / 
Solubilizer  
Polysorbate80 used to enhance disintegration and 
dissolution of Etodolac 
Binder Povidone (PVP) used for formation of granules. 
Glidant Colloidal silicon dioxide used as glidant 
Lubricant Magnesium stearate improves the rate of flow of 
tablet granules. 
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PREPARATION OF ETODOLAC IMMEDIATE RELEASE TABLETS 
 The ten different batches of Etodolac immediate release tablets 
were prepared and formulated by Wet Granulation method. And it involve 
the following procedure – 
 
PROCEDURE FOR FORMULATION OF ETODOLAC CONVENTIONAL 
TABLETS (F1) WITHOUT ADDING SUPERDISINTEGRANTS 
Step 1: Weigh all ingredients as per formula. 
Step 2: Sift LMH and MCC through sieve no. 40. 
Step 3: Mix step 2 powders with drug then pass through sieve no. 30. Mix 
the above powder for 15 minutes in a poly bag. 
Step 4: (Preparation of binder): Mix PVP with required quantity of water, 
then stirrer the solution until PVP dissolved completely, in that add 
polysorbate80 and mix well. Then immediately mix with step 3 powders to 
form granules. 
Step 5: (Drying): Keep the formed granules for air drying, after drying; 
pass the granules through 20 mesh to get uniform granules. 
Step 6: Sift magnesium stearate through sieve no. 40, mix it with colloidal 
silicon dioxide and step 5 granules for 2 minutes in a poly bag. 
Step 7: Now the blend (step 6) is compressed for target weight 490 mg 
using 12 mm flat punch. 
 
PROCEDURE FOR FORMULATION OF ETODOLAC IMMEDIATE 
RELEASE TABLETS WITH SUPERDISINTEGRANTS BY 
INTRAGRANULAR ADDITION METHOD (F2, F3 AND F4). 
Step 1: Weigh all ingredients as per formula. 
Step 2: [Intragranular (before granulation)]: Sift LMH, MCC and 
crospovidone and sodium starch glycolate through sieve no. 40. 
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Step 3: Mix step 2 powders with drug then pass through sieve no. 30. Mix 
the above powder for 15 minutes in a poly bag. 
Step 4: (Preparation of binder): Mix PVP with required quantity of water, 
then stirrer the solution until PVP dissolved completely, in that add 
polysorbate80 and mix well. Then immediately mix with step 3 powders to 
form granules. 
Step 5: (Drying): Keep the formed granules for air drying, after drying; 
pass the granules through 20 mesh to get uniform granules. 
Step 6: Sift magnesium stearate through sieve no. 40, mix it with colloidal 
silicon dioxide and step 5 granules for 2 minutes in a poly bag. 
Step 7: Now the blend (step 6) is compressed for target weight 490 mg 
using 12 mm flat punch. 
 
PROCEDURE FOR FORMULATION OF ETODOLAC IMMEDIATE 
RELEASE TABLETS WITH SUPERDISINTEGRANTS BY 
EXTRAGRANULAR ADDITION METHOD (F5, F6 AND F7). 
Step 1: Weigh all ingredients as per formula. 
Step 2: Sift LMH and MCC through sieve no. 40. 
Step 3: Mix step 2 powders with drug then pass through sieve no. 30. Mix 
the above powder for 15 minutes in a poly bag. 
Step 4: (Preparation of binder): Mix PVP with required quantity of water, 
then stirrer the solution until PVP dissolved completely, in that add 
polysorbate80 and mix well. Then immediately mix with step 3 powders to 
form granules. 
Step 5: (Drying): Keep the formed granules for air drying, after drying, 
pass the granules through 20 mesh to get uniform granules. 
Step 6: [Extragranular (After granulation)] Sift crospovidone and sodium 
starch glycolate, magnesium stearate through sieve no. 40, mix it with 
colloidal silicon dioxide and step 5 granules for 2 minutes in a poly bag. 
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Step 7: Now the blend (step 6) is compressed for target weight 490 mg 
using 12 mm flat punch. 
 
PROCEDURE FOR FORMULATION OF ETODOLAC IMMEDIATE 
RELEASE TABLETS WITH SUPERDISINTEGRANTS BY INTRA-
EXTRAGRANULAR ADDITION METHOD (F8, F9 AND F10). 
Step 1: Weigh all ingredients as per formula. 
Step 2: [Intragranular (before granulation)]: Sift LMH, MCC and 
crospovidone (polyplasdone XL-10), sodium starch glycolate through sieve 
no. 40. 
Step 3: Mix step 2 powders with drug then pass through sieve no. 30. Mix 
the above powder for 15 minutes in a poly bag. 
Step 4: (Preparation of binder): Mix PVP with required quantity of water, 
then stirrer the solution until PVP dissolved completely, in that add 
polysorbate80 and mix well. Then immediately mix with step 3 powders to 
form granules. 
Step 5: (Drying): Keep the formed granules for air drying, after drying, 
pass the granules through 20 mesh to get uniform granules. 
Step 6: [Extragranular (After granulation)] Sift crospovidone and sodium 
starch glycolate, magnesium stearate through sieve no. 40, mix it with 
colloidal silicon dioxide and step 5 granules for 2 minutes in a poly bag. 
Step 7: Now the blend (step 6) is compressed for target weight 490 mg 
using 12 mm flat punch. 
 
Chapter 8  Formulation of 
Etodolac IR Tablets 
 
 94
TABLE NO. 28: FORMULA OF ETODOLAC IMMEDIATE RELEASE 
TABLETS CONTAINING CROSPOVIDONE AND SODIUM STARCH 
GLYCOLATE BY “INTRAGRANULAR ADDITION METHOD” AT 
DIFFERENT CONCENTRATION (2%, 4% AND 6%) AND CONTROL 
TABLETS (F1) 
Quantity / Unit Dose (mg) 
S. No Ingredients 
F1 F2 F3 F4 
1. Etodolac 300 300 300 300 
2. Lactose monohydrate 98 
(20%)
78.5 
(15%)
58.8 
(12%) 
39.2 
(8%)
3. Microcrystalline cellulose (12.2%) 60 60 60 60 
4. Crospovidone, - 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%)
5. Sodium starch glycolate - 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%)
6. Povidone (3%) 14.7 14.7 14.7 14.7
7. Polysorbate 80 (1%) 4.9 4.9 4.9 4.9 
8. Colloidal silicon dioxide (1%) 4.9 4.9 4.9 4.9 
9. Magnesium stearate (1.5%) 7.35 7.35 7.35 7.35
10. Target weight of Etodolac IR tablet 490 490 490 490 
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TABLE NO. 29: FORMULA OF ETODOLAC IMMEDIATE RELEASE 
TABLETS CONTAINING CROSPOVIDONE AND SODIUM STARCH 
GLYCOLATE BY “EXTRAGRANULAR ADDITION” METHOD AT 
DIFFERENT CONCENTRATION (2%, 4% AND 6%) 
 
Quantity / Unit Dose (mg) 
S. No. Ingredients 
F5 F6 F7 
1. Etodolac 300 300 300 
2. Lactose monohydrate 78.5 
(15%) 
58.8 
(12%) 
39.2 
(8%) 
3. Microcrystalline cellulose (12.2%) 60  60 60 
4. Crospovidone 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%) 
5. Sodium starch glycolate 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%) 
6. Povidone (3%) 14.7 14.7 14.7 
7. Polysorbate 80 (1%) 4.9 4.9 4.9 
8. Colloidal silicon dioxide (1%) 4.9 4.9 4.9 
9. Magnesium stearate (1.5%) 7.35 7.35 7.35 
10. Target weight of Etodolac IR tablet 490 490 490 
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TABLE NO. 30: FORMULA OF ETODOLAC IMMEDIATE RELEASE 
TABLETS CONTAINING CROSPOVIDONE AND SODIUM STARCH 
GLYCOLATE BY “INTRA AND EXTRAGRANULAR ADDITION 
METHOD” AT DIFFERENT CONCENTRATION (2%, 4% AND 6%) 
 
Quantity / Unit Dose (mg) S. 
No. Ingredients F8 F9 F10 
1. Etodolac 300 300 300 
2. Lactose monohydrate 78.4 58.8 39.2 
3. Microcrystalline cellulose (12.2%) 60 60 60 
4. Crospovidone, 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%) 
5. Sodium starch glycolate 9.8 
(2%) 
19.6 
(4%) 
29.4 
(6%) 
6. Povidone (3%) 14.7 14.7 14.7 
7. Polysorbate 80 (1%) 4.9 4.9 4.9 
8. Colloidal silicon dioxide (1%) 4.9 4.9 4.9 
9. Magnesium stearate (1.5%) 7.35 7.35 7.35 
10. Target weight of Etodolac IR tablet 490 490 490 
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TABLE NO. 31: CONCENTRATION OF SUPERDISINTEGRANTS 
(CROSPOVIDONE AND SODIUM STARCH GLYCOLATE) IN ALL 
FORMULATION 
 
Superdisintegrants (Crospovidone (polyplasdone 
XL-10), Sodium Starch Glycolate) 
Intragranular Extragranular S. 
No. 
Formulation 
code 
Amount
(%) 
Concentration
(Mg) 
Amount
(%) 
Concentration
(Mg) 
1. F1(Control) - - - - 
2. F2 2 9.8 - - 
3. F3 4 19.6 - - 
4. F4 6 29.4 - - 
5. F5 - - 2 9.8 
6. F6 - - 4 19.6 
7. F7 - - 6 29.4 
  Intra and Extragranular 
8. F8 1 4.9 1 4.9 
9. F9 2 9.8 2 9.8 
10. F10 3 14.7 3 14.7 
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EVALUATION OF POWDERED BLEND 
 
EVALUATION OF POWDERED BLEND 
 Blend means a mixture of pure drug (Etodolac) and other excipients 
which was used in formulation. The prepared blend was evaluated for the 
following tests and the results were given in the table no. 32. 
• Angle of repose 
• Bulk density 
• Tapped density 
• Carr’s index / % compressibility index 
• Hausner’s ratio 
 
ANGLE OF REPOSE FOR PURE ETODOLAC DRUG POWDER 
 First a funnel was fixed at a particular height ‘h’ cm on a burette 
stand. A white paper was placed below the funnel on the table. The 
Etodolac powder drug whose angle of repose was to be determined was 
passed slowly through the funnel, until it forms a pile. Further addition of 
Etodolac powder was stopped as soon as the Etodolac powder pile 
touches the tip of the funnel. Circumferences of the pile of drug are drawn 
with a pencil without disturbing the pile. The radius of the pile was noted 
down as ‘r’ cm angle of repose θ0 of Etodolac pure drug was calculated by 
using the formula, and results are given in table no. 32. 
⎟⎠
⎞⎜⎝
⎛= −
r
htan 1θ  
where h = height of the pile 
 r = radius of the pile 
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BULK DENSITY FOR PURE ETODOLAC DRUG POWDER  
 Weighed and take 5 gm of pure Etodolac drug powder in measuring 
cylinder and calculate bulk density. 
Bulk density = 
0V
M  
where M = weight of active ingredient in grams 
 Vo = unsettled apparent volume in cm3 
 The unsettled apparent volume of pure drug of Etodolac in 
measuring cylinder was measured by normal scale. And the results are 
given in table no. 32. 
 
TAPPED DENSITY FOR PURE ETODOLAC DRUG POWDER 
 Weighed and take 5 gm of pure Etodolac drug powder in measuring 
cylinder. Tap it gently on a wooden surface from a height of 1 inch for 100 
times and calculate tapped density. And the results are given in  
table no. 32. 
Tapped density = 
Vf
M  
where M = weight of API, 
 Vf  = tapped volume 
 
COMPRESSIBILITY INDEX FOR PURE ETODOLAC DRUG POWDER  
 Compressibility index of pure Etodolac drug powder was calculated 
by following formula and results are given in table no. 32. 
Compressibility Index = ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −×
tapped
Bulktapped
ρ
ρρ
100
 
where ρtapped = tapped density 
 ρBulk = bulk density 
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HAUSNER’S RATIO FOR PURE ETODOLAC DRUG POWDER 
 Hausner’s ratio of pure Etodolac drug powder was calculated by 
following formula and results are given in table no. 32. 
Hauser ratio = ⎟⎟⎠
⎞
⎜⎜⎝
⎛
Bulk
tapped
ρ
ρ
 
 
ANGLE OF REPOSE FOR PURE ETODOLAC DRUG POWDER AND 
WITH OTHER EXCIPIENTS 
 First a funnel was fixed at a particular height ‘h’ cm on a burette 
stand. A white paper was placed below the funnel on the table. The 
Etodolac powder drug and with other excipients powder whose angle of 
repose was to be determined was passed slowly through the funnel, until it 
forms a pile. Further addition of Etodolac powder and other excipients 
powder was stopped as soon as the mixture of Etodolac drug powder and 
other excipients powder, pile touches the tip of the funnel. Circumferences 
of the pile of drug are drawn with a pencil without disturbing the pile. The 
radius of the pile was noted down as ‘r’ cm angle of repose θ0 of a mixture 
of Etodolac pure drug powder and other excipients powder and was 
calculated by using the formula, and results are given in table no. 32. 
 
BULK DENSITY FOR PURE ETODOLAC DRUG POWDER AND WITH 
OTHER EXCIPIENTS 
 Weighed and take 3 gm of pure Etodolac drug powder and with 
other excipients powder and mix it and pour in a measuring cylinder and 
calculate bulk density. The results are given in table no. 32. 
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TAPPED DENSITY FOR PURE ETODOLAC DRUG POWDER AND 
WITH OTHER EXCIPIENTS 
 Weighed and take 3 gm of pure Etodolac drug powder and with 
other excipients powder and mix it and pour in a measuring cylinder and 
calculate tapped density. The results are given in table no. 32. 
 
COMPRESSIBILITY INDEX FOR PURE ETODOLAC DRUG POWDER 
AND WITH OTHER EXCIPIENTS 
 Compressibility index of pure Etodolac drug powder and with other 
excipients powder was calculated by following formula and results are 
given in table no. 32. 
 
HAUSNER’S RATIO FOR PURE ETODOLAC DRUG POWDER AND 
WITH OTHER EXCIPIENTS 
 Hausner’s ratio of pure Etodolac drug powder and with other 
excipients powder was calculated by following formula and results are 
given in table no. 32. 
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TABLE NO. 32: ANGLE OF REPOSE, BULK DENSITY, TAPPED DENSITY, COMPRESSIBILITY INDEX, 
HAUSNER’S RATIO OF ETODOLAC PURE DRUG AND FORMULATED ETODOLAC IR TABLETS  
(F1, F2, F3, F4, F5, F6, F7, F8, F9 AND F10) 
 
S. 
No. Properties 
Pure 
drug F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1. Angle of repose (θ) 
35.47  
± 1.09 
26.58  
± 0.35 
27.39  
± 0.32 
27.39  
± 0.32 
27.39  
± 0.32 
26.41  
± 0.72 
26.41  
± 0.72 
26.41  
± 0.72 
25.89  
± 0.55  
25.89  
± 0.55 
25.89  
± 0.55 
2. Bulk density (gm/cm3) 0.33 0.69 0.73 0.73 0.73 0.74 0.74 0.74 0.75 0.75 0.75 
3. 
Tapped 
density 
(gm/cm3) 
0.41 0.78 0.81 0.81 0.81 0.82 0.82 0.82 0.83 0.8.3 0.83 
4. Carr’s index (%) 40 7.5 7.5 7.5 7.5 7.4 7.4 7.4 7.2 7.2 7.2 
5. Hausner ratio 1.6 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.07 1.07 1.07 
6. Flow property 
Very 
poor Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent 
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EVALUATION TESTS FOR ETODOLAC IR 
TABLETS 
 
 The formulated Etodolac IR tablets were evaluated for the following 
tests: 
1. General appearance: 
 a) Organoleptic properties (color, odor and taste) 
 b) Size and shape (thickness and diameter) 
2. Mechanical Strength of tablets: 
 a) Hardness or Crushing strength 
 b) Friability 
3. Weight variation 
4. Assay preparation 
5. Content Uniformity 
6. Disintegration  
7. Dissolution 
8. Compatibility studies 
• TLC 
•  IR 
 
GENERAL APPEARANCE 
 The general appearance of tablets, its visual identity and overall 
‘elegance’ is essential for consumer acceptance for monitoring the 
production process. The control of general appearance involves 
measurement of attributes such as a tablet’s size, shape, color, presence 
or absence of odour, taste, surface textures, physical flaws and 
consistency. 
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ORGANOLEPTIC PROPERTIES 
 Color is a vital means of identification. Reflectance 
Spectrophotometry, Tristimulus Colorimetric Measurements and Micro 
Reflectance Photometer have been used to measure color uniformity and 
gloss on a tablet surface. In preparation of Etodolac IR tablets no coloring 
agents were added. And the color of the Etodolac IR tablets was in off-
white. 
 Odor may also be important for consumer acceptance of tablets 
and can provide an indication of the quality of tablets. No odor was 
observed in Etodolac IR tablets. 
 Taste is also important for consumer acceptance of tablets. The 
taste of Etodolac IR tablets was checked. 
 
TABLET SIZE AND SHAPE 
 The shape and dimensions of compressed tablets are determined 
by the type of tooling during the compression process. 
 
TABLET THICKNESS 
 Tablets thickness varies with changes in die fill, particle size 
distribution and packing of the powder mix being compressed. The 
thickness of individual tablet of Etodolac IR tablets was measured with a 
Micrometer. Tablet thickness should be controlled within a ±5% variation of 
a standard value. At frequent time interval, from each batch 5 Etodolac IR 
tablets was taken and mean of 5 tablets was calculated and the results 
was given in the table no. 33. 
 
TABLET DIAMETER 
 The diameter of the Etodolac IR tablets was checked with Vernier 
calipers. At frequent time interval, from each batch 5 tablets was taken and 
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mean of 5 tablets was calculated and the results was given in the table no. 
33. 
 
MECHANICAL STRENGTH OF TABLETS 
 The mechanical strength of a tablet provides a measure of the 
bonding potential of the material concerned and this information is useful 
in the selection of excipients. 
 
HARDNESS OR CRUSHING STRENGTH 
 It is usually measured by the use of the Monsanto, Pfizer and 
Schleuniger. The resistance of the tablet to chipping, abrasion or breakage 
under conditions of storage, transportation and handling before usage 
depend on its results are given in table no. 34. 
 
FRIABILITY TEST 
 Friability test is usually measured by the use of the Roche 
Friabilator. Ten Etodolac IR tablets from each batch were weighed (Wo) 
initially and placed in a rotating drum. Then, they were subjected to 100 
revolutions. After completion of 100 revolutions or 4 minutes of time, the 
tablets were again weighed (W). The friability or loss in weight (f) was 
calculated by the formula given 
f = 1001 ×⎥⎦
⎤⎢⎣
⎡ −
OW
W  
 A maximum weight loss of not more than 1% of the weight of the 
tablets being tested during the friability test is considered generally 
acceptable and any broken or smashed tablets are not picked up. And 
results are given in table no. 34. 
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WEIGHT VARIATION 
 For uniformity of weight, twenty tablets from each batch of 
formulated Etodolac IR tablets were selected at random. The individual 
and total weight of 20 tablets from each batch was determined.  
 The results are given in table no. 34. Limit: Not more than two of the 
tablets must differ from the average weight by not more than the 
percentages. No tablet must differ by more than double the relevant 
percentage. 
 
CONTENT UNIFORMITY 
 For content uniformity test, representative samples of 30 tablets are 
selected and 10 are assayed individually. From each batch of formulated 
Etodolac IR tablets, ten tablets weighed and powdered. The powdered 
sample equivalent to Etodolac 50 mg was weighed and then taken in a 
stoppered test tube and extracted with 5 x 10 ml quantities of phosphate 
buffer pH 6.8. The extracts were filtered and collected into 100 ml of 
volumetric flask and made up to volume with phosphate buffer pH 6.8. And 
the solution were subsequently diluted suitably with phosphate buffer  
pH 6.8 and assayed for Etodolac IR tablets at 274 nm and the results are 
given in tablet. At least 9 must assay within ±15% of the declared potency 
and none may exceed ±25%. The results are given in table no. 34. 
 
ASSAY PREPARATION 
 Weigh and finely powder not less than 20 Etodolac IR tablets from 
each formulation. Remaining procedure is same as like content uniformity. 
Limit is Etodolac tablets contain not less than 90.0 percent and more than 
110.0 percent of the labeled amount of Etodolac. 
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TABLET DISINTEGRATION TEST 
 The disintegration time of Etodolac IR tablets was determined in 
distilled water using Remi Tablet Disintegration test machine of USP/IP 
standard. The results are given in table no. 34. If one or two tablets fail to 
disintegrate, the test is repeated using 12 tablets. For most uncoated 
tablets, the IP requires that the tablets disintegrate in 15 minutes. 
 
DISSOLUTION TEST 
 The dissolution rate of Etodolac IR tablets from various tablets 
prepared were studied using USP XXI Dissolution Rate Test Apparatus. 
(Lab India Disso 2000) employing paddle stirrer, as per dissolution rate 
prescribed in IP, for the above tablets the phosphate buffer of pH 6.8  
(900 ml) were used as dissolution fluids for Etodolac IR tablets. In each 
test one tablet, a speed 100 rpm rotations and a temperature of  
37°C ± 1°C were employed. A 10 ml aliquot of dissolution medium was 
withdrawn at different time interval suitable diluted and assayed 
spectrophotometrically at 274 nm for Etodolac. The percentage of drug 
dissolved at various time intervals 5, 10, 15, 20, 30, 45 min was calculated 
and plotted against time. The results are given in table no. 35 to 41. 
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TABLE NO. 33: APPEARANCE, THICKNESS AND DIAMETER OF ALL 
FORMULATED ETODOLAC IR TABLETS (F1- F10) 
S. 
No. 
Formulation 
code Appearance 
Diameter 
(mm) 
Thickness 
(mm) 
1. F1 12.5 ± 0.05 4.83 ± 0.75 
2. F2 12.6 ± 0.11 4.83 ± 0.75 
3. F3 12.4 ± 0.1 4.64 ± 0.75 
4. F4 12.5 ± 0.05 4.47 ± 0.75 
5. F5 12.5 ± 0.05 4.48 ± 0.09 
6. F6 12.4 ± 0.05 4.16 ± 0.18 
7. F7 12.8 ± 0.26 4.18 ± 0.07 
8. F8 12.5 ± 0.10 4.33 ± 0.06 
9. F9 12.6 ± 0.01 4.57 ± 0.04 
10. F10 *A
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12.6 ± 0.01 4.39 ± 0.06 
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TABLE NO. 34: HARDNESS, FRIABILITY, DISINTEGRATION TIME 
AND WEIGHT VARIATION AND CONTENT UNIFORMITY OF ALL 
FORMULATED ETODOLAC IR TABLETS (F1-F10) AND MARKET 
SAMPLE (MS) 
 
S. 
No. 
Formulation 
code 
Hardness 
(Kg/Cm2) 
Friability 
(%) 
Disintegration 
Time (Min and 
Sec) 
Average 
Weight 
(Limit 
range: 
465.5 - 
514.5) 
Content 
uniformity 
(%) 
1. F1 5.3 ± 0.10 0.78 38.5 ± 1.29 491.6 93.2 
2. F2 5.0 ± 0.20 0.62 14.75 ± 0.44 485.1 97.1 
3. F3 4.8 ± 0.10 0.81 13.00 ± 0.67 493.2 96.4 
4. F4 5.2 ± 0.1 0.57 11.51 ± 0.22 497.0 95.5 
5. F5 4.9 ± 0.15 0.72 10.94 ± 0.08 489.5 94.3 
6. F6 4.3 ± 0.10 0.58 10.16 ± 0.09 493.4 96.8 
7. F7 5.5 ± 0.10 0.73 9.60 ± 0.06 488.7 101.1 
8. F8 5.1 ± 0.15 0.69 8.63 ± 0.15 492.3 98.6 
9. F9 5.6 ± 0.10 0.85 4.70 ± 0.05 491.4 98.9 
10. F10 4.8 ± 0.15 0.83 4.50 ± 0.15 490.9 99.5 
11. MS 4.9 ± 0.10 0.81 7.51 ± 0.11 - - 
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TABLE NO. 35: DISSOLUTION PROFILE OF ETODOLAC IR TABLETS 
CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND SODIUM 
STARCH GLYCOLATE BY INTRAGRANULAR (F2, F3, AND F4) AND 
CONTROL TABLET (F1) 
 
% of Etodolac Drug Release in pH 6.8 
S. no. Time in mins F1 F2 F3 F4 
1. 5 12.3 ± 1.68 17.5 ± 1.16 19.1 ± 1.35 21.2 ± 1.40
2. 10 13.1 ± 1.15 28.1 ± 0.85 30.2 ± 1.32 31.4 ± 1.15
3. 15 14.7 ± 1.08 38.7 ± 1.46 40.7 ± 0.97 41.6 ± 0.99
4. 30 16.8 ± 0.96 63.5 ± 1.58 68.6 ± 1.07 70.8 ± 1.68
5 45 18.6 ± 1.04 74.8 ± 1.45 77.5 ± 1.03 80.1 ± 1.43
 
FIGURE NO. 8: IN VITRO DRUG RELEASE PROFILE OF ETODOLAC 
IR TABLETS, CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND 
SODIUM STARCH GLYCOLATE BY INTRAGRANULAR (F2, F3, AND 
F4) AND CONTROL TABLET (F1) 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45 50
Time in minutes
%
 o
f E
to
do
la
c 
D
ru
g 
R
el
ea
se
 in
 p
H
 6
.8
F1 F2 F3 F4  
Chapter 10  Evaluation of 
Etodolac IR Tablets 
 
 111
TABLE NO. 36: DISSOLUTION PROFILE OF ETODOLAC IR TABLETS 
CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND SODIUM 
STARCH GLYCOLATE BY EXTRAGRANULAR (F5, F6, AND F7) 
 
% of Etodolac Drug Release in pH 6.8 
S. No. Time in Mins 
F5 F6 F7 
1. 5 24.5 ± 1.71 28.6 ± 1.18 29.4 ± 1.06 
2. 10 48.5 ± 1.08 54.6 ± 1.18 55.9 ± 1.62 
3. 15 56.1 ± 0.68 59.8 ± 1.03 60.9 ± 0.97 
4. 30 65.4 ± 0.85 70.1 ± 0.74 71.8 ± 1.02 
5. 45 70.0 ± 0.67 75.91 ± 0.65 77.95 ± 1.12 
 
FIGURE NO. 9: IN VITRO DRUG RELEASE PROFILE OF ETODOLAC IR 
TABLETS, CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND SODIUM 
STARCH GLYCOLATE BY EXTRAGRANULAR (F5, F6, AND F7) 
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TABLE NO. 37: DISSOLUTION PROFILE OF ETODOLAC IR TABLETS 
CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND SODIUM 
STARCH GLYCOLATE BY INTRA AND EXTRAGRANULAR (F8, F9, 
AND F10) 
 
% of Etodolac Drug Release in pH 6.8 
S. No. Time in Mins 
F8 F9 F10 
1. 5 46.3 ± 1.41 62.4 ± 1.72 78.9 ± 1.85 
2. 10 61.5 ± 1.75 76.1 ± 1.84 85.0 ± 2.83 
3. 15 79.6 ± 0.98 88.5 ± 2.56 92.9 ± 1.72 
4. 30 87.6 ± 1.08 93.0 ± 1.68 97.7 ± 1.57 
5. 45 92.6 ± 1.52 96.1 ± 1.54 100.8 ± 1.89 
 
FIGURE NO. 10: IN VITRO DRUG RELEASE PROFILE OF ETODOLAC 
IR TABLETS CONTAINING 2%, 4%, 6% OF CROSPOVIDONE AND 
SODIUM STARCH GLYCOLATE BY INTRA AND EXTRAGRANULAR 
(F8, F9, AND F10) 
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TABLE NO. 38: DISSOLUTION PROFILE OF ALL FORMULATED 
ETODOLAC IR TABLETS AND MARKET SAMPLE 
 
% of drug release S. 
No 
Time 
in 
mins F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 MI 
1. 5 
12.3 
± 
1.68 
17.5 
± 
1.16 
19.1 
± 
1.35 
21.2 
± 
1.40 
24.5 
± 
1.71 
28.6 
± 
1.18 
29.4 
± 
1.06 
46.3 
± 
1.41 
62.4 
± 
1.72 
78.9 
± 
1.85 
21.6 
2. 10 
13.1 
± 
1.15 
28.1 
± 
0.85 
30.2 
± 
1.32 
31.4 
± 
1.15 
48.5 
± 
1.08 
54.6 
± 
1.18 
55.9 
± 
1.62 
61.5 
± 
1.75 
76.1 
± 
1.84 
85.0 
± 
2.83 
46.3 
3. 15 
14.7 
± 
1.08 
38.7 
± 
1.46 
40.7 
± 
0.97 
41.6 
± 
0.99 
56.1 
± 
0.68 
59.8 
± 
1.03 
60.9 
± 
0.97 
79.6 
± 
0.98 
88.5 
± 
2.56 
92.9 
± 
1.72 
54.9 
4. 30 
16.8 
± 
0.96 
63.5 
± 
1.58 
68.6 
± 
1.07 
70.8 
± 
1.68 
65.4 
± 
0.85 
70.1 
± 
0.74 
71.8 
± 
1.02 
87.6 
± 
1.08 
93.0 
± 
1.68 
97.7 
± 
1.57 
67.5 
5. 45 
18.6 
± 
1.04 
74.8 
± 
1.45 
77.5 
± 
1.03 
80.1 
± 
1.43 
70.0 
± 
0.67 
75.91 
± 
0.65 
77.95 
± 
1.12 
92.6 
± 
1.52 
96.1 
± 
1.54 
100.8 
± 
1.89 
84.7 
 
FIGURE NO. 11: IN VITRO DRUG RELEASE PROFILE OF ALL 
FORMULATED ETODOLAC IR TABLETS AND MARKET SAMPLE 
Chapter 10  Evaluation of 
Etodolac IR Tablets 
 
 114
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45 50
Time in minutes
%
 o
f E
to
do
la
c 
D
ru
g 
R
el
ea
se
 in
 p
H
 6
.8
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10  
TABLE NO. 39: DISSOLUTION PROFILE COMPARISON OF 
ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
“INTRAGRANULAR” (F2, F3, AND F4) AND “EXTRAGRANULAR”  
(F5, F6, AND F7) AND CONTROL TABLET (F1) 
% of Etodolac drug release in pH 6.8 
S. 
No. 
Time 
in 
Mins F1 F2 F3 F4 F5 F6 F7 
1. 5 12.3  
± 1.68 
17.5 
 ±1.16
19.1  
± 1.35
21.2  
± 1.40
24.5 
 ±1.71
28.6  
± 1.18 
29.4  
± 1.06
2. 10 13.1  
± 1.15 
28.1  
± 0.85
30.2  
± 1.32
31.4  
± 1.15
48.5  
± 1.08
54.6  
± 1.18 
55.9  
± 1.62
3. 15 14.7  
± 1.08 
38.7  
± 1.46
40.7  
± 0.97
41.6  
± 0.99
56.1  
± 0.68
59.8  
± 1.03 
60.9  
± 0.97
4. 30 16.8  
± 0.96 
63.5  
± 1.58
68.6  
± 1.07
70.8  
± 1.68
65.4  
± 0.85
70.1  
± 0.74 
71.8  
± 1.02
5. 45 18.6  
± 1.04 
74.8  
± 1.45
77.5  
± 1.03
80.1  
± 1.43
70.0  
± 0.67
75.91 
± 0.65 
77.95 
± 1.12
 
FIGURE NO 12: IN VITRO DRUG RELEASE PROFILE COMPARISON 
OF ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
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“INTRAGRANULAR” (F2, F3, AND F4) AND “EXTRAGRANULAR” 
(F5, F6, AND F7) AND CONTROL TABLET (F1) 
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TABLE NO. 40: DISSOLUTION PROFILE COMPARISON OF 
ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
“INTRAGRANULAR” (F2, F3, AND F4) AND “INTRA + 
EXTRAGRANULAR” (F8, F9 AND F10) AND CONTROL TABLET (F1) 
% of Etodolac drug release in pH 6.8 
S. 
No. 
Time 
in 
Mins F1 F2 F3 F4 F8 F9 F10 
1. 5 12.3  ± 1.68 
17.5  
± 1.16 
19.1  
± 1.35 
21.2  
± 1.40 
46.3  
± 1.41 
62.4  
± 1.72 
78.9  
± 1.85 
2. 10 13.1  ± 1.15 
28.1  
± 0.85 
30.2  
± 1.32 
31.4  
± 1.15 
61.5  
± 1.75 
76.1  
± 1.84 
85.0  
± 2.83 
3. 15 14.7  ± 1.08 
38.7  
± 1.46 
40.7  
± 0.97 
41.6  
± 0.99 
79.6  
± 0.98 
88.5  
± 2.56 
92.9  
± 1.72 
4. 30 16.8  ± 0.96 
63.5  
± 1.58 
68.6  
± 1.07 
70.8  
± 1.68 
87.6  
± 1.08 
93.0  
± 1.68 
97.7  
± 1.57 
5. 45 18.6  ± 1.04 
74.8  
± 1.45 
77.5  
± 1.03 
80.1  
± 1.43 
92.6 
 ± 1.52 
96.1  
± 1.54 
100.8 
± 1.89 
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FIGURE NO. 13: IN VITRO DRUG RELEASE PROFILE COMPARISON 
OF ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
“INTRAGRANULAR” (F2, F3, AND F4) AND “INTRA + 
EXTRAGRANULAR” (F8, F9, AND F10) AND CONTROL TABLET 
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TABLE NO. 41: DISSOLUTION PROFILE COMPARISON OF 
ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
“EXTRAGRANULAR” (F5, F6, AND F7) AND “INTRA + 
EXTRAGRANULAR” (F8, F9, AND F10) AND CONTROL TABLET (F1) 
% of Etodolac drug release in pH 6.8 
S. No. Time in Mins F1 F5 F6 F7 F8 F9 F10 
1. 5 12.3  
± 1.68 
24.5  
± 1.71 
28.6  
± 1.18 
29.4  
± 1.06 
46.3  
± 1.41 
62.4  
± 1.72 
78.9  
± 1.85 
2. 10 13.1  
± 1.15 
48.5  
± 1.08 
54.6  
± 1.18 
55.9  
± 1.62 
61.5  
± 1.75 
76.1  
± 1.84 
85.0  
± 2.83 
3. 15 14.7  
± 1.08 
56.1   
± 0.68 
59.8  
± 1.03 
60.9  
± 0.97 
79.6  
± 0.98 
88.5  
± 2.56 
92.9  
± 1.72 
4. 30 16.8  
± 0.96 
65.4  
± 0.85 
70.1  
± 0.74 
71.8  
± 1.02 
87.6  
± 1.08 
93.0  
± 1.68 
97.7  
± 1.57 
5. 45 18.6  
± 1.04 
70.0  
± 0.67 
75.91 
± 0.65 
77.95 
± 1.12 
92.6  
± 1.52 
96.1  
± 1.54 
100.8 
± 1.89 
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FIGURE NO. 14: IN VITRO DRUG RELEASE PROFILE COMPARISON 
OF ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY 
“EXTRAGRANULAR” (F5, F6, AND F7) AND “INTRA + 
EXTRAGRANULAR” (F8, F9, AND F10) AND CONTROL TABLET (F1) 
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TABLE NO. 42: t50 AND t90 OF ALL FORMULATED ETODOLAC IR 
TABLETS (F1-F10) 
 
t50 t90 
S. No. Formulation Code 
pH 6.8 
1. F1 - - 
2. F2 22.75 - 
3. F3 20.00 - 
4. F4 19.00 - 
5. F5 11.25 - 
6. F6 9.00 - 
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7. F7 8.00  
8. F8 6.25 30 
9. F9 4.00 17.5 
10. F10 2.30 8.5 
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TABLE NO. 43: DISSOLUTION PROFILE COMPARISON OF 
ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY “INTRA + 
EXTRAGRANULAR” (F8, F9, AND F10) AND MARKET SAMPLE (MS) 
 
% of Etodolac drug release in pH 6.8 
S. No. Time in Mins 
F8 F9 F10 MS 
1. 5 46.3 ± 1.41 62.4 ± 1.72 78.9 ± 1.85 21.6
2. 10 61.5 ± 1.75 76.1 ± 1.84 85.0 ± 2.83 46.3
3. 15 79.6 ± 0.98 88.5 ± 2.56 92.9 ± 1.72 54.9
4. 30 87.6 ± 1.08 93.0 ± 1.68 97.7 ± 1.57 67.5
5. 45 92.6 ± 1.52 96.1 ± 1.54 100.8 ± 1.89 84.5
 
FIGURE NO. 15: IN VITRO DRUG RELEASE PROFILE COMPARISON 
OF ETODOLAC IR TABLETS CONTAINING 2%, 4%, 6% OF 
CROSPOVIDONE AND SODIUM STARCH GLYCOLATE BY “INTRA + 
EXTRAGRANULAR” (F8, F9, AND F10) AND MARKET SAMPLE (MS) 
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STABILITY STUDIES 
 
REAL TIME STABILITY STUDY 
Among all formulated Etodolac immediate release tablets, 
formulation F10 was selected based on its release in the dissolution 
medium phosphate buffer pH 6.8 and it is kept in the real time stability 
chamber for stability studies. After specified period of time, the samples 
were collected and the percentage of drug release and assay was 
calculated and the percentage of drug release and assay was calculated 
and the graph was plotted between time vs. percentage of Etodolac 
released. The results were given in the table no. 44 to 48 and  
figure no. 16. 
 
Accelerated stability study 
 Among all formulated Etodolac immediate release tablets, 
formulation F10 was selected based on its release in the dissolution 
medium, and phosphate buffer pH 6.8 and it is kept in the accelerated 
stability chamber for stability studies. After specified period of time, the 
samples were collected and the percentage of drug release and assay 
was calculated and the graph was plotted between time vs. percentage of 
Etodolac released. The results were given in the table no. 44 to 48 and  
figure no. 17. 
 
Chapter 10  Evaluation of 
Etodolac IR Tablets 
 
 121
TABLE NO. 44: STABILITY STUDY TEST TO BE CONDUCTED FOR 
ETODOLAC IR TABLET DOSAGE FORM 
 
S. No. Test Stability criteria 
1. Assay 90.0 – 110.0 % of label 
2. Degradation production Not more than 0.3% each 
3. Dissolution Q = 80% in 45 min (USP acceptance criteria) 
4. Appearance No significant difference from a control stored at 5oC 
5. Disintegration Based on dissolution 
6. Hardness - 
7. Content uniformity Within the limit 
8. Friability Based on hardness 
9. Water content (Karl Fischer titration) - 
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TABLE NO. 45: COMPARISON OF PHYSICAL PARAMETER OF 
STABILITY FORMULATION (F10) IN REAL TIME AND ACCELERATED 
STABILITY STUDY WITH INITIAL MONTH 
 
Long term/real time 
stability study 
Accelerated stability 
study 
Parameter 
Initial 
/ zero 
month 1st 
month
2nd 
month
3rd 
month
1st 
month
2nd 
month 
3rd 
month
Appearance * * * * * * * 
Thickness 
(mm) 
4.39 ± 
0.06 
4.39 ± 
0.06 
4.39 ± 
0.06 
4.39 ± 
0.065 
4.39 ± 
0.06 
4.39 ± 
0.06 
4.39 ± 
0.065 
Diameter 
(mm) 
12.6 ± 
0.01 
12.6 ± 
0.0108
12.6 ± 
0.0108
12.6 ± 
0.0108
12.6 ± 
0.0108
12.6 ± 
0.0108 
12.6 ± 
0.0108
Hardness 
(kg/cm2) 
4.8 ± 
0.15 
4.8 ± 
0.15 
4.8 ± 
0.15 
4.8 ± 
0.15 
4.8 ± 
0.15 
4.8 ± 
0.15 
4.8 ± 
0.15 
Friability (% 
w/w) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
Disintegration 
time (min/sec) 
4.50 ± 
0.15 
4.61 ± 
0.1 
4.62 ± 
0.1 
4.62 ± 
0.15 
4.61 ± 
0.15 
4.71 ± 
0.15 
4.71 ± 
0.15 
* white, flat, circular, beveledged, uncoated tablet with a mark SRIPMS on 
one surface. 
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TABLE NO. 46: DISSOLUTION PROFILE OF STABILITY 
FORMULATION (F10) IN REAL TIME STABILITY CONDITION 
% of drug released 
Time in 
mins Initial / zero 
month 1
st month 2nd month 3rd month 
5 78.9 ± 1.85 75.9 ± 2.15 74.1 ± 2.35 73.9 ± 2.94 
10 85.0 ± 2.83 84.1 ± 2.35 82.5 ± 2.56 81.2 ± 2.69 
15 92.9 ± 1.72 91.9 ± 1.62 91.5 ± 1.58 90.9 ± 1.84 
30 97.7 ± 1.57 95.4 ± 1.64 94.6 ± 1.68 92.9 ± 1.62 
45 100.8 ± 1.89 99.8 ± 1.59 99.6 ± 1.25 99.4 ± 1.05 
 
FIGURE NO. 16: IN VITRO DRUG RELEASE PROFILE OF STABILITY 
FORMULATION (F10) IN REAL TIME STABILITY CONDITION 
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TABLE NO. 47: DISSOLUTION PROFILE OF STABILITY 
FORMULATION (F10) IN ACCELERATED STABILITY CONDITION 
% of drug released 
Time in 
mins Initial / zero 
month 1
st month 2nd month 3rd month 
5 78.9 ± 1.85 75.9 ± 4.50 74.1 ± 3.25 73.9 ± 1.94 
10 85.0 ± 2.83 83.1 ± 4.15 82.5 ± 2.46 80.2 ± 2.98 
15 92.9 ± 1.72 91.4 ± 1.95 90.1 ± 1.56 89.9 ± 1.96 
30 97.7 ± 1.57 94.6 ± 1.60 93.2 ± 1.40 91.5 ± 1.92 
45 100.8 ± 1.89 98.2 ± 0.98 98.4 ± 1.24 97.4 ± 1.21 
 
FIGURE NO. 17: IN VITRO DRUG RELEASE PROFILE OF STABILITY 
FORMULATION (F10) IN ACCELERATED STABILITY CONDITION 
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TABLE NO. 48: ASSAY OF STABILITY FORMULATION (F10) IN REAL 
TIME AND ACCELERATED STABILITY CONDITION 
 
Amount of drug / tablet Initial / zero 
month 1st month 2nd month 3rd month Stability Condition 
Mg % Mg % Mg % Mg % 
Real time 300.78 101.8 300.14 100.12 299.91 100.01 299.78 99.87
Accelerate 300.78 101.8 300.25 100.05 299.75 99.92 299.04 99.68
 
COMPATIBILITY STUDIES 
 Preservation of the chemical integrity of the drug substance during 
intended shelf life of the product is the fundamental prerequisite toward 
successful formulation of any drug delivery system. The crucial 
requirement is thus the confirmation of the absence of chemical interaction 
between the drug and the excipients. Many techniques like diffuse 
reflectance spectroscopy, accelerated storage tests TLC, IR and thermal 
methods are employed for the detection of potential interaction. 
 
THIN LAYER CHROMATOGRAM 
A thin layer chromatographic method was also carried to study the 
interaction between the drug and excipient and also to confirm the 
chemical stability of the Etodolac drug in IR tablet. For this, the pure 
Etodolac drug and the formulated Etodolac IR tablet with various 
excipients by Wet granulation method were subjected to chromatographic 
studies. 
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The following TLC system was used 
Precoated TLC plates : Manufactured by SD Fine Chemicals 
Ltd., Mumbai. 
Adsorbant layer : Silica gel GF254 
Layer thickness : 0.22 mm 
Size : 10 × 20 cm 
Separation technique : Ascending 
Chamber saturation rate : The chamber was lined on 3 sides with 
filter paper saturated for 30 minutes 
Solvent front : 5.3 cm 
Solvent system : Glacial acetic acid:Ethanol:Toulene 
(0.5:30:70) 
Preparation of samples : Dissolve 10 mg of the Etodolac in 
acetone and dilute to 10 ml with the 
same solvent. The resultant solution is 
used for spotting. 
Amount Applied : 10µl. 
Detection : Short and long wave length of UV light. 
 The Rf values obtained are given in the table no. 49. 
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TABLE NO. 49: TLC DATA FOR ETODOLAC PURE DRUG AND 
ETODOLAC IR TABLETS WITH OTHER EXCIPIENTS 
 
SAMPLE Rf VALUES NUMBER OF SPOTS 
Etodolac (pure) 0.49 Single 
Etodolac IR tablet with excipients 
F1 (control) 0.49 Single 
F2 (with SD) 0.51 Single 
F3 (with SD) 0.51 Single 
F4 (with SD) 0.51 Single 
F5 (with SD) 0.54 Single 
F6 (with SD) 0.54 Single 
F7 (with SD) 0.54 Single 
F8 (with SD) 0.52 Single 
F9 (with SD) 0.52 Single 
F10 (with SD) 0.52 Single 
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Etodolac
x
F2 F3 F4F1
x x xx
F8 F9 F10
x x x
F5 F6 F7
x x x
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INFRARED SPECTRUM 
 Principal peaks at wavenumbers 1746, 1412, 1034, 748 cm−1 (KBr 
pellet). 
 
 
IR SPECTRAL ANALYSIS 
 Fourier Transform infrared (FT-IR) spectra of the samples were 
obtained in the range of 700-1800 cm-1 using a FT- IR Jasco 410 
spectrophotometer (Jasco. Essex) by the KBr disc method. The IR spectra 
of various immediate release Etodolac tablets and pure drug of Etodolac 
were obtained in figure no. 18 to 21. 
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FIGURE NO. 18: IR SPECTRA OF ETODOLAC PURE DRUG 
 
FIGURE NO. 19: IR SPECTRA OF FORMULATION F8 (DRUG + 
EXCIPIENT) 
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FIGURE NO. 20: IR SPECTRA OF FORMULATION F9 (DRUG + 
EXCIPIENT) 
 
 
FIGURE NO. 21: IR SPECTRA OF FORMULATION F10 (DRUG + 
EXCIPIENT) 
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RESULTS AND DISCUSSION 
 
 An attempt was made to develop immediate release tablets of 
Etodolac to increase the rate of dissolution by using intragranular, 
extragranular and partly intra and extragranular method of addition of 
crospovidone, sodium starch glycolate as superdisintegrants. 
 Nine batches (F2-F10) of Etodolac immediate tablets were 
prepared with crospovidone, sodium starch glycolate at three different 
concentrations (2%, 4% and 6%) by wet granulation method. The same 
way one control batch (F1) is prepared without addition of 
superdisintegrants. Lactose monohydrate, colloidal silicon dioxide PVP, 
MCC, magnesium stearate, and polysorbate 80 are used as excipients for 
the above formulations. 
 
COMPATIBILITY STUDIES 
 The compatibility between the drug and excipients were evaluated 
by using TLC and IR matching approach.  
 
THIN LAYER CHROMATOGRAPHY 
 In TLC studies, Etodolac dispersed in various excipients showed 
the same Rf value as pure compound and no additional spots were 
detected. TLC studies thus indicated no interaction between Etodolac and 
excipients in the immediate release tablets formulated. This observation 
also indicated that Etodolac was not decomposed during the formulation of 
immediate release tablets. 
 
FT-IR SPECTRAL ANALYSIS 
 In IR studies, there was no appearance or disappearance of 
characteristics peaks in pure drug and drug excipient mixture. In Etodolac 
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IR spectrum, principal peaks at wave numbers were noticed at 1746, 
1412, 1034, 748 cm−1 (KBr pellet). The IR spectra obtained are given in 
figure no. 18-21. 
 This two methods (TLC and IR) conformed that the absence of any 
chemical interaction between drug and excipients. 
 
FLOW PROPERTIES 
 Powder blend of drug and excipients were prepared and evaluated 
for pre-compressional parameters such as angle of repose, bulk density, 
tapped density, percentage compressibility index and Hausner’s 
compressibility ratio (table no. 32) all for formulation (F1-F10) were found to 
be excellent in their flow property. The flow property of pure drug was very 
poor. 
 
EVALUATION OF ETODOLAC FORMULATED TABLETS 
 All the formulated Etodolac immediate release tablets (F1-F10) 
were fulfilled official requirements for weight variation and drug content 
uniformity (table no. 34). All the tablets prepared were found to contain the 
medicament within 100±7.5% of labeled claim (table no. 34) Hardness of 
the tablets in all the batches were found to be in the range of  
4.3 to 5.6 kg/m2 (table no. 34) and was satisfactory. The percentage 
weight loss in the friability test was found to be less than 1% in all 
formulations (table no. 34) were found to be good quality fulfilling the 
official requirements of compressed tablets. And the appearance, 
thickness, diameter (table no. 33) was found to be good quality fulfilling the 
general requirements of compressed tablets. 
 All the formulated Etodolac immediate release tablets containing 
crospovidone, sodium starch glycolate were disintegrated within 15 min, 
fulfilling official requirements for compressed tablets, (table no. 34) where 
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as the disintegrating time of control tablet (F1) was more when compared 
with Etodolac formulated IR tablets (F2-F10). 
 The order of disintegration was found to be 
F10 > F9 > F8 > F7 > F6 > F5 > F4 > F3 > F2 > F1. 
 The formulation containing partly intra and extragranular method of 
addition of disintegrants (F8, F9 and F10) shows faster disintegration than 
the intragranular (F2, F3 and F4) and extragranular (F5, F6 and F7) 
formulation. 
 The faster disintegration of F8-F10 formulation containing sodium 
starch glycolate and crospovidone by partly intra and extragranular 
addition method may be due to immediate disruption of tablet into 
previously compressed granules by the extragranular while the sodium 
starch glycolate and crospovidone, disintegrating agents within the 
granules (intragranular) producers further erosion of the granules to the 
original powder particles. Therefore the two step method (partly intra and 
extragranular) usually produce better and more complete disintegration 
than the other two method of addition of disintegrants. 
 
DISSOLUTION STUDIES 
 The percentage drug released at different time periods (5, 10, 15, 
30 and 45 min) from Etodolac immediate release tablets in pH 6.8 
phosphate buffer is shown in table no. 35 to 41 and figure no. 8 to 14. The 
percentage of drug release in F1 formulation was found to be 18.6%, 
whereas the percentage of drug release in F2, F3 and F4 formulation was 
found to be 74.8%, 77.5% and 80.1%. Where as the percentage of drug 
release in F5, F6 and F7 formulation was found to be 70.0%, 75.91% and 
77.95% and the percentage of drug release in F8, F9 and F10 formulation 
was found to be 92.6%, 96.1% and 100.8%. 
 The t50 and t90 of all the formulation is shown in the table no. 42 
Among the batches formulated, formulation F10 released 90% of the drug 
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within 8.5 mins and 50% of the drug in 2.3 min; hence it was selected as a 
best formulation among all nine formulations for immediate release 
preparation. 
 Among the tablets formulated F10 formulation release 78.9% of 
drug release, where as in case of control F1 and marketed sample MS the 
drug release was 12.3% and 21.6% only. 
 
STABILITY STUDIES 
 The stability studies were carried out on formulation 10 according to 
ICH guidelines. At real time and accelerated storage condition there was 
slight change in the hardness, friability, disintegration time and release 
characteristics which were acceptable. 
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CONCLUSION 
 
9 Attempts were made to increase the rate of drug release 
(disintegration) to enhance the in vitro dissolution of the poorly 
soluble drug Etodolac by using extra, intra and partly  intra and 
extra granular method of addition of sodium starch glycolate and 
crospovidone as superdisintegrants and to develop a stable 
immediate release formulation by wet granulation method. 
9 Chemical incompatibilities study confirmed that there is no 
interaction between drug and excipients need in the formulation.  
9 The flow properties of the powdered blend for all the formulation 
(F2-F10) were found to be excellent.  
9 The weight variation, drug content uniformity, hardness, friability, 
thickness, and diameter of all the formulated tablets were within the 
specified requirements. The disintegration time for the formulated 
tablets was less than the control tablets (F1) and market samples 
(MS) were within the specified limits. 
9 In vitro dissolution study showed that the formulation F10 shows 
higher percentage of drug release when compared to control tablet 
and market sample with respect to t50 to t90. The improvement in the 
dissolution may be due to increase in the rate of drug release 
(disintegration) by sodium starch glycolate and crospovidone as 
superdisintegrants by partly intra and extra granular addition 
method. 
9 Hence, the Etodolac can be formulated as immediate release 
tablets for better pain management. 
9 Further work was carried out for in vivo studies. 
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